STOCK TITAN

Medicus Pharma offers about $3M in shares and warrants

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
424B5

Rhea-AI Filing Summary

Medicus Pharma Ltd. (MDCX) is offering 97,973 common shares and pre-funded warrants to purchase up to 1,646,213 common shares, at $1.72 per share and $1.7199 per warrant. Each warrant covers one share, is immediately exercisable at $0.0001 per share, and carries a 4.99% beneficial-ownership limit, or 9.99% at the holder’s election. Gross proceeds are approximately $3.0 million before expenses, excluding warrant-exercise proceeds.

Closing depends on a concurrent private placement of 726,730 shares for approximately $1.25 million, including at least $1.1 million in gross cash proceeds at no less than $1.72 per share, funded from purchasers’ own resources rather than conversion or cancellation of company obligations. Separately, Streeterville exchanged $10.5 million principal under the A-1 Note for 105,000 non-convertible, non-voting preferred shares; the exchanged debt was extinguished, and the preferred shares carry cumulative 8% dividends payable in kind.

Medicus disclosed substantial doubt about its ability to continue as a going concern. As of September 30, 2026, it had approximately $5.0 million in cash and equivalents, $8.1 million in restricted cash and $21.0 million in debentures and secured notes by carrying amount. The company says the offering and private-placement proceeds, together with existing cash, will not fund planned operations for an extended period and that it needs substantial additional capital.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 1 point

How the balance works

Positive

  • None.

Negative

  • Major pointSubstantial doubt about the company’s ability to continue as a going concern.
Common shares offered 97,973 shares Registered offering
Common shares underlying pre-funded warrants Up to 1,646,213 shares Registered offering
Common-share offering price $1.72 per share The November 12, 2026 closing price
Pre-funded warrant offering price $1.7199 per warrant Offering price per warrant
Pre-funded warrant exercise price $0.0001 per share Exercise price for each common share
Offering gross proceeds Approximately $3.0 million Before estimated offering expenses; excludes any proceeds from warrant exercises
Concurrent private placement 726,730 common shares; approximately $1.25 million gross proceeds Shares sold at $1.72 per share
Concurrent note exchange $10.5 million principal exchanged for 105,000 preferred shares Streeterville exchanged principal under the A-1 Note
pre-funded warrants technical
"pre-funded warrants to purchase up to 1,646,213 common shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
cashless exercise technical
"exercise its pre-funded warrant by means of a cashless exercise"
A cashless exercise is a way for an option holder to convert stock options into actual shares without paying the purchase price in cash; instead they immediately give up a portion of the newly issued shares to cover the cost and any withholding taxes. Investors care because this process increases the number of shares available and can slightly dilute existing holdings, while also signaling how insiders or employees are realizing compensation without needing cash — similar to paying for a purchase by handing over part of what you just bought.
beneficial ownership limitation regulatory
"the beneficial ownership limitation may in no event exceed 9.99%"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
at-the-market program financial
"sold approximately 113,000 common shares under our at-the-market program"
An at-the-market program is a way for a company to sell new shares of its stock gradually over time directly into the stock market, rather than all at once. This approach allows the company to raise money as needed while giving investors the opportunity to buy shares at current market prices. It helps manage the timing and price of new stock offerings, providing flexibility for both the company and investors.
going concern financial
"substantial doubt about our ability to continue as a going concern"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
net tangible book value financial
"Our net tangible book value as of September 30, 2026"
Net tangible book value is the per-share value of a company if you take all its physical assets and cash, subtract what it owes, and ignore intangible items like patents or brand names. Think of it like the cash you’d split among owners if a business sold its furniture and buildings but not its reputation. Investors use it as a conservative benchmark to judge whether a stock is cheaply priced relative to hard, sellable assets.
Offering Type shelf
Securities Offered 97,973 common shares; pre-funded warrants to purchase up to 1,646,213 common shares; 1,646,213 common shares underlying the pre-funded warrants
Price Range $1.72 per common share; $1.7199 per pre-funded warrant
Offering Amount 97,973 common shares and pre-funded warrants to purchase up to 1,646,213 common shares
Use of Proceeds Working capital, including continued development of product candidates and/or repayment of indebtedness.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much gross proceeds does MDCX expect from this offering?

Medicus expects approximately $3.0 million in gross proceeds before estimated offering expenses, excluding proceeds from exercise of the pre-funded warrants. It expects approximately $1.25 million in gross proceeds from the separate concurrent private placement.

What securities and prices are included in MDCX’s offering?

The company is offering 97,973 common shares at $1.72 each and pre-funded warrants to purchase up to 1,646,213 common shares at $1.7199 each. Each warrant is exercisable for one share at $0.0001 per share and is immediately exercisable.

Is MDCX’s offering conditional on the concurrent private placement?

Yes. The offering is conditioned on the private placement closing and the company receiving at least $1.1 million in gross cash proceeds from common shares sold at no less than $1.72 per share. Purchasers must use their own resources, not convert or cancel an existing company obligation.

Will MDCX pre-funded warrants trade on an exchange?

There is no established public trading market for the pre-funded warrants, and the company does not expect one to develop or intend to apply to list them on an exchange or nationally recognized trading system. The prospectus states that their liquidity will be limited without an active market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Filed Pursuant to Rule 424(b)(5)

Registration No. 333-292475

PROSPECTUS SUPPLEMENT

(To Prospectus dated December 29, 2025)

97,973 Common Shares

Pre-Funded Warrants to Purchase up to 1,646,213 Common Shares

1,646,213 Common Shares Underlying the Pre-Funded Warrants

We are offering 97,973 of our common shares, no par value (the "common shares"), and pre-funded warrants to purchase up to 1,646,213 common shares (the "pre-funded warrants") directly to certain investors pursuant to this prospectus supplement, the base prospectus and a securities purchase agreement, dated November 13, 2026, between us and such investors (the "securities purchase agreement"). The offering price is $1.72 per common share, which was the closing price of our common shares on The Nasdaq Capital Market ("Nasdaq") on November 12, 2026, and $1.7199 per pre-funded warrant, which is equal to the offering price per common share minus $0.0001, the exercise price per share of each pre-funded warrant. We are offering pre-funded warrants, in lieu of common shares, to any investor whose purchase of common shares in this offering would otherwise result in such investor, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the investor, 9.99%) of our outstanding common shares immediately following the consummation of this offering. Each pre-funded warrant is exercisable for one common share, is immediately exercisable and may be exercised at any time until all of the pre-funded warrants are exercised in full. This prospectus supplement and the base prospectus also relate to the offering of the common shares issuable upon exercise of the pre-funded warrants (the "pre-funded warrant shares" and, together with the common shares and the pre-funded warrants offered hereby, the "securities").

We are selling the securities directly to the investors without the use of a placement agent, underwriter, broker or dealer, and we will not pay any underwriting discounts, commissions or placement agent fees in connection with this offering. The aggregate gross proceeds to us from this offering will be approximately $3.0 million, before deducting estimated offering expenses payable by us and excluding any proceeds from the exercise of the pre-funded warrants. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. We provide more information about how the securities will be sold in the section entitled "Plan of Distribution."

Concurrently with this offering, (i) we are selling, in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), 726,730 common shares at the same price per share as the common shares sold in this offering, for aggregate gross proceeds of approximately $1.25 million, to a limited number of accredited investors, consisting primarily of members of our management and directors, including Dr. Raza Bokhari, our Executive Chairman and Chief Executive Officer (the “concurrent private placement”), and (ii) we have issued 105,000 of our non-convertible, non-voting preferred shares (the “Preferred Shares”) to Streeterville Capital, LLC in exchange for $10.5 million in principal amount of our outstanding indebtedness (the “concurrent note exchange” and, together with the concurrent private placement, the “concurrent transactions”). The securities issued in the concurrent transactions are not being offered pursuant to this prospectus supplement and the base prospectus. This offering is conditioned upon the consummation of the concurrent private placement. See “Prospectus Summary—Recent Developments—Concurrent Private Placement” and “—Concurrent Note Exchange.”

Our common shares are listed on Nasdaq under the symbol "MDCX". On November 12, 2026, the closing price of our common shares as reported by Nasdaq was $1.72 per share. There is no established public trading market for the pre-funded warrants, and we do not expect a market to develop. We do not intend to apply to list the pre-funded warrants on any securities exchange or nationally recognized trading system.


Investing in our securities involves a high degree of risk. See "Risk Factors" beginning on page S-9 of this prospectus supplement and under similar headings in the documents incorporated by reference into this prospectus supplement.

Neither the Securities and Exchange Commission (the "SEC") nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.

We expect to deliver the common shares to the investors through the facilities of The Depository Trust Company, and the pre-funded warrants in certificated form, on or about November 13, 2026, subject to the satisfaction of customary closing conditions.

The date of this prospectus supplement is November 13, 2026.


TABLE OF CONTENTS

Prospectus Supplement

ABOUT THIS PROSPECTUS SUPPLEMENT S-1
TRADEMARKS, TRADE NAMES AND SERVICE MARKS S-2
MARKET, INDUSTRY AND OTHER DATA S-2
CAUTIONARY NOTE CONCERNING FORWARD-LOOKING STATEMENTS S-2
PROSPECTUS SUMMARY S-4
THE OFFERING S-7
RISK FACTORS S-9
USE OF PROCEEDS S-13
DIVIDEND POLICY S-14
DESCRIPTION OF THE SECURITIES WE ARE OFFERING S-15
DILUTION S-18
CERTAIN MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS S-20
PLAN OF DISTRIBUTION S-26
LEGAL MATTERS S-27
EXPERTS S-27
WHERE YOU CAN FIND MORE INFORMATION S-27
INFORMATION INCORPORATED BY REFERENCE S-27
   
Prospectus  
   
ABOUT THIS PROSPECTUS 1
TRADEMARKS, TRADE NAMES AND SERVICE MARKS 2
MARKET, INDUSTRY AND OTHER DATA 3
CAUTIONARY NOTE CONCERNING FORWARD-LOOKING STATEMENTS 4
OUR BUSINESS 6
RISK FACTORS 10
USE OF PROCEEDS 11
DILUTION 12
DESCRIPTION OF THE SECURITIES THAT MAY BE OFFERED 13
PLAN OF DISTRIBUTION 17
LEGAL MATTERS 21
EXPERTS 21
WHERE YOU CAN FIND MORE INFORMATION 21
INFORMATION INCORPORATED BY REFERENCE 21


ABOUT THIS PROSPECTUS SUPPLEMENT

This prospectus supplement relates to part of a registration statement on Form S-3 (File No. 333-292475) that we have filed with the SEC utilizing a "shelf" registration process. Under this shelf registration process, we may sell any combination of the securities described in our base prospectus included in the shelf registration statement in one or more offerings up to a total aggregate offering price of $100,000,000. The securities that are being offered, issued and sold under this prospectus supplement are included in the $100,000,000 of securities that may be offered, issued and sold by us pursuant to our shelf registration statement. In connection with such offers and when accompanied by the base prospectus included in the registration statement of which this prospectus supplement is a part, this prospectus supplement will be deemed a prospectus supplement to such base prospectus.

We provide information to you about this offering of our securities in two separate documents: (i) this prospectus supplement, which describes the specific details regarding this offering; and (ii) the base prospectus referred to on the cover page of this prospectus supplement, which provides general information, some of which may not apply to this offering. Generally, when we refer to the "prospectus," we are referring to both documents combined. You should read both this prospectus supplement and the base prospectus as well as the information contained in the documents incorporated by reference herein and the additional information described in this prospectus supplement under the headings "Where You Can Find More Information" and "Information Incorporated by Reference" before investing in our securities. These documents contain important information that you should consider when making your investment decision. This prospectus supplement describes the terms of this offering of securities and also adds to and updates information contained in the documents incorporated by reference into this prospectus supplement. To the extent there is a conflict between the information contained in this prospectus supplement or any document incorporated by reference herein filed prior to the date of this prospectus supplement, you should rely on the information in this prospectus supplement; provided that if any statement in one of these documents is inconsistent with a statement in another document having a later date - for example, a document incorporated by reference in this prospectus supplement - the statement in the document having the later date modifies or supersedes the earlier statement.

You should rely only on the information contained or incorporated herein by reference in this prospectus supplement. We have not authorized any other person to provide you with any information that is different. If anyone provides you with different, additional or inconsistent information, you should not rely on it.

We are offering to sell our securities only in jurisdictions where offers and sales are permitted. The distribution of this prospectus supplement and the offering of the securities in certain jurisdictions may be restricted by law. This prospectus supplement does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation.

We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference in the prospectus, including the securities purchase agreement, were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.

You should not consider any information in this prospectus supplement or the base prospectus to be investment, legal or tax advice. You should consult your own counsel, accountants and other advisers for legal, tax, business, financial and related advice regarding the purchase of the securities offered by this prospectus supplement.

Unless otherwise indicated, all share and per share amounts in this prospectus supplement give effect to the 1-for-50 share consolidation effected by the Company on October 12, 2026 (the "Share Consolidation"). The share and per share amounts contained in the base prospectus and in the documents incorporated by reference herein that were filed with the SEC prior to October 12, 2026 do not give effect to the Share Consolidation. These documents include our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as amended, and our Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2026 and June 30, 2026.

In this prospectus supplement, unless otherwise indicated or the context otherwise requires, references to "we," "us," "our," the "Company" and "Medicus" refer to the consolidated operations of Medicus Pharma Ltd. and its subsidiaries.


We have authorized only the information contained or incorporated by reference in this prospectus supplement, the base prospectus, and any free writing prospectus prepared by or on behalf of us or to which we have referred you. We have not authorized anyone to provide you with information that is different. We take no responsibility for, and can provide no assurance as to the reliability of, any information that others may give you. We are offering to sell, and seeking offers to buy, our securities only in jurisdictions where offers and sales are permitted. The information contained in or incorporated by reference in this document is accurate only as of the date such information was issued, regardless of the time of delivery of this prospectus supplement or the date of any sale of our securities.

TRADEMARKS, TRADE NAMES AND SERVICE MARKS

This prospectus supplement, including the information incorporated by reference herein, contains references to trademarks and service marks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus supplement and documents incorporated by reference in this prospectus supplement may appear without the ® or ™ symbols, but such references are not intended to indicate, in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. We do not intend our use or display of other companies' trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of them by, any other companies.

MARKET, INDUSTRY AND OTHER DATA

This prospectus supplement, including the information incorporated by reference herein, contains estimates, projections and other information concerning our industry, our business, and the markets for certain products and services, including data regarding the estimated size of those markets and their projected growth rates. Information that is based on estimates, forecasts, projections or similar methodologies is based on a number of assumptions and is inherently subject to uncertainties, including those described in "Risk Factors" and elsewhere in this prospectus supplement and documents incorporated by reference in this prospectus supplement, and actual events or circumstances may differ materially from events and circumstances reflected in this information. You are cautioned not to give undue weight to such estimates, projections and other information.

CAUTIONARY NOTE CONCERNING FORWARD-LOOKING STATEMENTS

This prospectus supplement and the documents incorporated by reference herein include forward-looking statements that involve substantial risks and uncertainties. These include forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), as well as forward-looking information within the meaning of applicable Canadian securities laws. All statements, other than statements of historical facts, included or incorporated by reference in this prospectus supplement regarding our strategy, future operations, regulatory process, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. The words "believe", "anticipate", "intend", "expect", "target", "goal", "estimate", "plan", "assume", "may", "will", "predict", "project", "would", "could" and similar expressions or the negative of such terms are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

The forward-looking statements included or incorporated by reference in this prospectus supplement include, but are not limited to, statements about:

• our ability to regain and maintain compliance with the continued listing requirements of Nasdaq, including the minimum shareholders' equity requirement, and the expected effect of this offering and the concurrent transactions on our shareholders' equity;

• the expected accounting treatment of the concurrent note exchange and the Preferred Shares, including the classification of the Preferred Shares as permanent shareholders' equity;

• our expected use of the proceeds from this offering and the concurrent private placement;

• our financial results, including our ability to continue as a going concern, generate earnings and achieve and sustain profitability, which may vary significantly from forecasts and from period to period;

• the progress, timing and completion of our research, development and preclinical studies and clinical trials for our products and product candidates;


• our ability to successfully develop CD228V (as defined herein) and realize the benefits currently anticipated from the Pfizer Agreement (as defined herein);

• our ability to enter into definitive agreements relating to the proposed business combination between SkinJect, Inc. and a special purpose acquisition company (the "SkinJect Business Combination") and to consummate the proposed SkinJect Business Combination and the related equity financing;

• our ability to successfully integrate Antev (as defined herein) into our business and operations, successfully develop Teverelix (as defined herein) and realize the benefits currently anticipated from the transaction;

• our ability to market, commercialize, achieve market acceptance for and sell our products and product candidates;

• our ability to develop, manage and maintain our direct sales and marketing organizations;

• our estimates regarding anticipated operating losses, future revenues, capital requirements and our needs for additional financing;

• market risks regarding consolidation in the healthcare, pharmaceutical and biotech/life sciences industry;

• the willingness of healthcare providers to purchase our products if coverage, reimbursement and pricing from third party payors for procedures using our products significantly declines;

• our ability to adequately protect our intellectual property and operate our business without infringing upon the intellectual property rights of others;

• the fact that product quality issues or product defects may harm our business;

• the market price of our securities may be volatile and fluctuate substantially, which could cause the value of your investment to decline;

• any product liability claims; and

• the regulatory, legal and certain operating risks that our operations subject us to.

We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this prospectus supplement and in the documents incorporated by reference herein that could cause actual results or events to differ materially from the forward-looking statements that we make. These include, in particular, the factors described in the "Risk Factors" section of this prospectus supplement and the factors under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025, as amended (the "Annual Report"), and in our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026 (the "Q3 10-Q"), each incorporated by reference herein. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make.

You should read this prospectus supplement and the documents incorporated by reference herein, completely and with the understanding that our actual future results may be materially different from what we expect. We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are subject to risks, uncertainties and assumptions about us, including those listed in the section of this prospectus supplement entitled "Risk Factors", in the section entitled "Risk Factors" in our Annual Report, in the Q3 10-Q and in our other filings which are incorporated by reference herein.

Any forward-looking statement made by us is based on information available to us at the time of such statement and speaks only as of the date on which it was made. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.


PROSPECTUS SUMMARY

This summary highlights selected information contained elsewhere in this prospectus supplement and in the documents we incorporate by reference herein. This summary does not contain all of the information you should consider before investing in our securities. You should read this entire prospectus carefully, especially the risks of investing in our securities discussed under "Risk Factors" beginning on page S-9 of this prospectus supplement and under similar sections of the other periodic reports incorporated herein by reference.

Our Company

We are a precision-guided, clinical-stage biotech and life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets. Our current therapeutic assets are:

• CD228V, an investigational antibody-drug conjugate ("ADC") directed against melanotransferrin (CD228), a cell-surface protein expressed across multiple solid tumor types, such as melanoma, squamous non-small cell lung cancer, head and neck squamous cell carcinoma and esophageal cancer. CD228V uses Pfizer Inc.'s ("Pfizer") established vedotin linker-payload platform. CD228V is our principal development priority, with an initial focus on establishing clinical proof-of-concept in melanoma;

• SkinJect® ("SkinJect"), an investigational localized immuno-oncology product candidate using dissolvable doxorubicin-containing microneedle arrays ("D-MNA"). We are developing SkinJect exclusively for the treatment of basal cell carcinoma ("BCC") lesions in patients with Gorlin syndrome, a rare autosomal dominant disease also known as nevoid BCC syndrome; and

• Teverelix® ("Teverelix"), an investigational next-generation gonadotropin-releasing hormone ("GnRH") antagonist. We are developing Teverelix as a potential first-in-market product for advanced prostate cancer patients at increased cardiovascular risk, for patients with acute urinary retention relapse episodes due to enlarged prostate and for patients with symptomatic endometriosis.

Our strategy is to advance select programs through Phase 2 proof-of-concept and key clinical and regulatory inflection points that we believe substantially reduce development risk and increase their attractiveness to potential pharmaceutical partners. By generating decision-grade clinical, regulatory and operational datasets, we seek to create opportunities for strategic collaborations, regional licensing transactions and broader commercialization partnerships with established pharmaceutical companies, while maintaining capital efficiency and development focus. We also seek to opportunistically identify, evaluate and acquire accretive assets, properties or businesses.

Through our wholly owned subsidiary, Medicus Pharma Inc., we are party to a Co-Development and License Agreement with Pfizer, dated September 2, 2026 (the "Pfizer Agreement"), pursuant to which we obtained an exclusive worldwide license to develop, manufacture and commercialize CD228V. Through our wholly owned subsidiary, SkinJect, Inc., we are developing SkinJect, an in-licensed drug-device combination product. Through our 98.6%-owned subsidiary, Antev Limited ("Antev"), which we acquired in August 2025, we are developing Teverelix.

Prior to the Company's acquisition of SkinJect, Inc., our business was undertaken by SkinJect, Inc. as a stand-alone entity. References to our business as conducted at a date prior to the completion of our business combination with SkinJect, Inc. on September 29, 2023 relate to the business undertakings of SkinJect, Inc.

We are subject to significant risks and uncertainties, including those related to our limited operating history, our lack of historical earnings, and the fact that our product candidates are novel technologies for which regulatory approval might not be achieved. For more information, see "Risk Factors."

For a description of our corporate structure as well as corporate history and information regarding the Company please see the documents incorporated by reference herein, which are identified under the headings "Where You Can Find More Information" and "Information Incorporated by Reference" in this prospectus supplement.

Our website address is www.medicuspharma.com. Information contained on our website is not incorporated by reference into this prospectus supplement, and you should not consider information contained on our website to be part of this prospectus supplement or in deciding whether to purchase our securities.

Recent Developments

Concurrent Private Placement

Concurrently with this offering, we entered into agreements with a limited number of accredited investors, consisting primarily of members of our management and directors, including Dr. Raza Bokhari, our Executive Chairman and Chief Executive Officer (purchasing through a controlled entity). Under these agreements, we agreed to issue and sell an aggregate of 726,730 common shares at a purchase price of $1.72 per share, which is the same as the offering price per common share in this offering and the closing price of our common shares on Nasdaq on November 12, 2026. Aggregate gross proceeds will be approximately $1.25 million, including approximately $750,000 from Dr. Bokhari. The common shares to be issued in the concurrent private placement are being offered and sold in reliance on the exemptions from registration provided by Section 4(a)(2) of the Securities Act and/or Regulation S thereunder. They have not been registered under the Securities Act, are not being offered pursuant to this prospectus supplement and the base prospectus, and will be “restricted securities” within the meaning of Rule 144 under the Securities Act. The concurrent private placement is expected to close on or about November 13, 2026, subject to customary closing conditions.


The closing of this offering is conditioned upon our receipt of not less than $1.1 million in gross cash proceeds from the sale of common shares in the concurrent private placement, at a price per share not less than $1.72, funded from the purchasers' own resources and not through the conversion or cancellation of any existing obligation of ours.

Concurrent Note Exchange

On November 13, 2026, we entered into and closed an exchange agreement (the "Exchange Agreement") with Streeterville Capital, LLC ("Streeterville"). Under the Exchange Agreement, $10.5 million in principal amount of our Secured Promissory Note A-1, issued on May 27, 2026 in the original principal amount of $12,864,225 (the "A-1 Note"), was partitioned from the A-1 Note into a new note (the "Partitioned Note"), and Streeterville exchanged the Partitioned Note for 105,000 non-convertible, non-voting Preferred Shares at an issue price of $100 per Preferred Share. Upon the closing of the exchange, the Partitioned Note was cancelled, the indebtedness exchanged under the A-1 Note was extinguished and our obligations under the A-1 Note were reduced by the $10.5 million principal amount so exchanged. The unexchanged balance of the A-1 Note remains outstanding in accordance with its terms and continues to be secured by the security interests, guaranties and collateral agreements relating to the A-1 Note. Our Secured Promissory Note A-2, issued on September 1, 2026 (the "A-2 Note" and, together with the A-1 Note, the "A Notes"), was not affected by the exchange. Following the exchange, approximately $4.2 million of principal and accrued and unpaid interest remains outstanding under the A Notes, and the $8.2 million outstanding under our Secured Promissory Note B, issued on May 27, 2026, was also not affected by the exchange. We did not receive any cash proceeds from the exchange.

The Preferred Shares are not convertible into common shares and do not carry voting rights, except as required by the Business Corporations Act (Ontario). The Preferred Shares carry cumulative dividends at a rate of 8% per annum, payable in kind in additional Preferred Shares. The Preferred Shares are redeemable solely at our option, upon prior written notice, at a redemption price of $100 per Preferred Share plus all declared and unpaid dividends thereon to, but excluding, the redemption date, without premium or penalty. Holders of the Preferred Shares have no right to require us to redeem the Preferred Shares. Upon a liquidation, dissolution or winding up of the Company, the holders of the Preferred Shares are entitled to receive $100 per Preferred Share plus all declared and unpaid dividends thereon, in priority to the holders of our common shares. We expect to classify the Preferred Shares as permanent shareholders' equity. The Preferred Shares were issued in reliance on the exemption from registration provided by Section 3(a)(9) of the Securities Act or, alternatively, Section 4(a)(2) of the Securities Act, and are not being offered pursuant to this prospectus supplement and the base prospectus.

The closing of this offering is not conditioned upon the closing of the concurrent note exchange.

At-the-Market Program

From October 1, 2026 through November 12, 2026, we sold approximately 113,000 common shares for gross proceeds of approximately $0.35 million under our at-the-market program.

Nasdaq Listing Matters

On May 20, 2026, we received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying us that our market value of listed securities had been below $35 million for the previous 30 consecutive business days. As a result, we were not in compliance with Nasdaq Listing Rule 5550(b)(2). The notice also stated that we did not then satisfy either of the alternative continued listing standards under Nasdaq Listing Rule 5550(b)(1) or 5550(b)(3). We were provided a compliance period of 180 calendar days, or until November 16, 2026, to regain compliance with the market value of listed securities requirement or to satisfy an alternative listing standard. One such alternative is the requirement under Nasdaq Listing Rule 5550(b)(1) to maintain shareholders' equity of at least $2.5 million (the "Equity Standard"). As of September 30, 2026, we had a total shareholders' deficit of approximately $10.5 million.


We believe that this offering, the concurrent transactions and the sale of common shares under our at-the-market program since September 30, 2026 will cause us to satisfy the Equity Standard. There can be no assurance that Nasdaq will make such a determination, or that we will be able to maintain compliance with the Equity Standard or Nasdaq's other continued listing requirements in the future. See "Risk Factors-Risks Related to this Offering and to our Common Shares-This offering and the concurrent transactions are intended to strengthen our balance sheet and to help us regain compliance with Nasdaq's shareholders' equity requirement, but there can be no assurance that we will regain or maintain compliance with Nasdaq's continued listing requirements, and our common shares could be delisted."

Implications of Being an Emerging Growth Company

As a company with less than $1.235 billion in revenues during our last fiscal year, we qualify as an "emerging growth company" as that term is defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). As an emerging growth company we expect to take advantage of specified reduced reporting requirements that are otherwise applicable generally to public companies. These reduced reporting requirements include, but are not limited to:

• not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended ("Sarbanes-Oxley Act");

• reduced disclosure about our executive compensation arrangements in our periodic reports, proxy statements and registration statements; and

• an exemption from the requirements to obtain a non-binding advisory vote on executive compensation or shareholder approval of any golden parachute arrangements.

We may take advantage of these provisions until the last day of our fiscal year following the fifth anniversary of the completion of our initial public offering in the United States. However, if certain events occur prior to the end of such five-year period, we will cease to be an emerging growth company prior to the end of such five-year period. These events include becoming a "large accelerated filer," our annual gross revenues exceeding $1.235 billion or our issuing more than $1 billion of non-convertible debt in any three-year period.

The JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. As an emerging growth company, we intend to take advantage of an extended transition period for complying with new or revised accounting standards as permitted by the JOBS Act. We have elected to take advantage of certain of the reduced disclosure obligations in this prospectus supplement and in the registration statement of which this prospectus supplement is a part and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information in this prospectus supplement and that we provide to our shareholders in the future may be different than what you might receive from other public reporting companies in which you hold equity interests.

Implications of Being a Smaller Reporting Company

Additionally, we are a "smaller reporting company," as defined in Rule 12b-2 under the Exchange Act. As such, we are eligible for exemptions from various reporting requirements applicable to other public companies that are not smaller reporting companies, including, but not limited to, reduced disclosure obligations regarding executive compensation. We may continue to be a smaller reporting company as long as either (i) the market value of our common shares held by non-affiliates is less than $250 million or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our common shares held by non-affiliates is less than $700 million, in each case measured as of the last business day of our most recently completed second fiscal quarter.


THE OFFERING

Issuer Medicus Pharma Ltd.
   
Common shares offered by us pursuant to this prospectus supplement 97,973 common shares.
Pre-funded warrants offered by us We are also offering pre-funded warrants to purchase up to 1,646,213 common shares to any investor whose purchase of common shares in this offering would otherwise result in such investor, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the investor, 9.99%) of our outstanding common shares immediately following the consummation of this offering. The pre-funded warrants are offered in lieu of common shares. The purchase price of each pre-funded warrant is equal to the price at which a common share is sold in this offering, minus $0.0001, and the exercise price of each pre-funded warrant is $0.0001 per share. Each pre-funded warrant is exercisable for one common share (subject to adjustment as provided therein), is exercisable immediately and may be exercised at any time until all of the pre-funded warrants are exercised in full. This prospectus supplement and the base prospectus also relate to the offering of the pre-funded warrant shares. See "Description of the Securities We Are Offering-Pre-Funded Warrants."
   
Offering price $1.72 per common share and $1.7199 per pre-funded warrant.
   
Common shares outstanding prior to this offering 1,963,403 common shares as of November 12, 2026.
   
Common shares outstanding after this offering(1) 3,707,589 common shares, assuming the exercise in full of the pre-funded warrants and excluding the common shares to be issued in the concurrent private placement. After also giving effect to the issuance of 726,730 common shares in the concurrent private placement, 4,434,319 common shares.
   
Concurrent transactions Concurrently with this offering, (i) we are selling 726,730 common shares to a limited number of accredited investors, consisting primarily of members of our management and directors, including our Executive Chairman and Chief Executive Officer, in the concurrent private placement at the same price per share as the common shares sold in this offering, for aggregate gross proceeds of approximately $1.25 million, and (ii) Streeterville exchanged $10.5 million in principal amount of the A-1 Note for 105,000 Preferred Shares in the concurrent note exchange. Neither the common shares sold in the concurrent private placement nor the Preferred Shares are being offered pursuant to this prospectus supplement. This offering is conditioned upon the consummation of the concurrent private placement. See “Prospectus Summary—Recent Developments—Concurrent Private Placement” and “—Concurrent Note Exchange.”
   
Manner of offering We are offering the securities directly to the investors pursuant to the securities purchase agreement, without the use of a placement agent, underwriter, broker or dealer. See "Plan of Distribution."
   
Use of proceeds The gross proceeds to us from this offering will be approximately $3.0 million, excluding the proceeds, if any, from the exercise of the pre-funded warrants. We intend to use the proceeds from this offering, together with the proceeds from the concurrent private placement, for working capital purposes, including to fund the continued development of our product candidates and/or the repayment of indebtedness. See "Use of Proceeds."



Market for common shares Our common shares are listed on Nasdaq under the symbol "MDCX." There is no established public trading market for the pre-funded warrants, and we do not expect a market to develop. We do not intend to list the pre-funded warrants on any securities exchange or nationally recognized trading system. Without an active trading market, the liquidity of the pre-funded warrants will be limited.
   
Transfer agent Odyssey Trust Company.
   
Risk factors See "Risk Factors" beginning on page S-9 of this prospectus supplement, as well as the other information included in or incorporated by reference in this prospectus supplement, for a discussion of risks you should carefully consider before investing in our securities.

(1) The number of common shares that will be outstanding after this offering is based on 1,963,403 common shares outstanding as of November 12, 2026. It assumes the exercise in full of the pre-funded warrants and excludes, as of that date: (i) common shares issuable upon the exercise of outstanding incentive awards; (ii) common shares issuable upon the exercise of outstanding warrants; (iii) any common shares that may be issued pursuant to the Company's at-the-market program.


RISK FACTORS

Before you make a decision to invest in our securities, you should consider carefully the risks described below, together with other information in this prospectus supplement and the information incorporated by reference herein, including any risk factors contained in our Annual Report, our Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2026, June 30, 2026 and September 30, 2026 and other reports filed with the SEC. If any of the following events actually occur, our business, operating results, prospects or financial condition could be materially and adversely affected. This could cause the trading price of our common shares to decline and you may lose all or part of your investment. The risks described below are not the only ones that we face. Additional risks not presently known to us or that we currently deem immaterial may also significantly impair our business operations and could result in a complete loss of your investment.

Risks Related to this Offering and to our Common Shares

This offering and the concurrent transactions are intended to strengthen our balance sheet and to help us regain compliance with Nasdaq's shareholders' equity requirement, but there can be no assurance that we will regain or maintain compliance with Nasdaq's continued listing requirements, and our common shares could be delisted.

As described under "Prospectus Summary-Nasdaq Listing Matters," we are currently not in compliance with Nasdaq's market value of listed securities requirement. We have until November 16, 2026 to regain compliance with that requirement or to satisfy an alternative continued listing standard, such as the Equity Standard, which requires us to maintain shareholders' equity of at least $2.5 million. As of September 30, 2026, we had a total shareholders' deficit of approximately $10.5 million. We are conducting this offering and the concurrent transactions in order to, among other things, increase our shareholders' equity above the level required by the Equity Standard. While we believe that following this offering and the concurrent transactions we will satisfy the Equity Standard, Nasdaq has not yet made a compliance determination and there is no assurance that, even if we regain compliance presently, we will maintain compliance with the Equity Standard or any other applicable continued listing requirement in the future.

In addition, we expect to continue to incur significant operating losses, which will reduce our shareholders' equity over time. Even if Nasdaq determines that we have regained compliance, we expect that Nasdaq will continue to monitor our ongoing compliance with the Equity Standard. If at the time we file our next periodic report we do not evidence compliance, we may be subject to delisting.

We must also continue to satisfy Nasdaq's other continued listing requirements, including the $1.00 minimum bid price requirement. We regained compliance with the minimum bid price requirement on October 23, 2026 following the Share Consolidation. However, the trading price of our common shares has declined significantly since the Share Consolidation became effective. Under Nasdaq's rules, we have effected a reverse share split within the prior one-year period. As a result, if our common shares fail to satisfy the minimum bid price requirement during such one-year period, we will not be eligible for any compliance period to cure such deficiency, and Nasdaq could issue a delisting determination with respect to our common shares.

If our common shares are delisted, market liquidity for our common shares could be severely affected and our shareholders' ability to sell their common shares could be limited. A delisting of our common shares from Nasdaq would negatively affect the value of our common shares and the pre-funded warrants. It could also adversely affect our ability to obtain financing for our operations and could result in the loss of confidence in our Company. In addition, a delisting could cause our common shares to be considered a "penny stock," which would subject broker-dealers trading in our common shares to more stringent rules. A delisting could also result in an event of default or other adverse consequences under the terms of our outstanding indebtedness.

Even after giving effect to this offering and the concurrent transactions, we will need substantial additional funding, and there is substantial doubt about our ability to continue as a going concern.

As of September 30, 2026, we had cash and cash equivalents of approximately $5.0 million and restricted cash of approximately $8.1 million. We also had debentures and secured promissory notes with an aggregate carrying amount of approximately $21.0 million outstanding. In the concurrent note exchange, $10.5 million in principal amount of the A-1 Note was exchanged for Preferred Shares. There is substantial doubt about our ability to continue as a going concern. The proceeds from this offering and the concurrent private placement, together with our existing cash and cash equivalents, will not be sufficient to fund our planned operations for an extended period. We will need to raise substantial additional capital to continue the development of our product candidates and to repay or refinance our outstanding indebtedness. Additional financing may not be available on acceptable terms, or at all, and any additional equity financing will dilute our existing shareholders. If we are unable to obtain sufficient additional funding when needed, we may be required to delay, reduce or eliminate our development programs, or to cease operations.


Since we have broad discretion in how we use the proceeds from this offering, we may use the proceeds in ways with which you disagree.

While we intend to use the proceeds of the offering for working capital purposes, our management will have flexibility in applying the proceeds of this offering. You will be relying on the judgment of our management with regard to the use of these proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that the proceeds will be invested in a way that does not yield a favorable, or any, return for us. The failure of our management to use such funds effectively could have a material adverse effect on our business, financial condition, operating results and cash flow.

This offering and the concurrent private placement will substantially increase the number of our outstanding common shares, which could cause the market price of our common shares to decline.

As of November 12, 2026, we had 1,963,403 common shares outstanding. Assuming the exercise in full of the pre-funded warrants, we will issue an aggregate of 2,470,916 common shares in this offering and the concurrent private placement. This represents approximately 126% of our common shares outstanding prior to this offering. The issuance of such a significant number of common shares relative to our outstanding common shares, and the resale of such shares in the public market, or the perception that such resales may occur, could cause the market price of our common shares to decline significantly.

Sales of a significant number of our common shares in the public markets, or the perception that such sales could occur, could depress the market price of our common shares.

The common shares sold in this offering, including the pre-funded warrant shares, will be freely tradable without restriction or further registration under the Securities Act, unless held by our affiliates. In addition, we may sell common shares having an aggregate offering price of up to approximately $31 million remaining under our at-the-market program. The common shares issued in the concurrent private placement will become eligible for resale under Rule 144 under the Securities Act, subject to the volume limitations and other conditions applicable to sales by affiliates. In addition, subject to compliance with applicable securities laws, our officers, directors and significant shareholders may sell some or all of their common shares in the future. Sales of a substantial number of our common shares in the public markets could depress the market price of our common shares and impair our ability to raise capital through the sale of additional equity securities. We cannot predict the effect that future sales of our common shares would have on the market price of our common shares.

Our shareholders may experience substantial dilution in the value of their investment if we issue additional securities.

To raise additional capital, we may in the future sell additional common shares or other securities convertible into or exchangeable for our common shares at prices that are lower than the prices paid by investors in this offering. Investors purchasing shares or other securities in the future could have rights superior to existing shareholders, which could result in substantial dilution to the interests of existing shareholders. In addition, shareholders may experience further dilution to the extent that outstanding warrants or options are exercised, new options or other equity awards are issued under our equity incentive plan, or we issue additional shares in the future.

We have in the past, and may in the future, issue debt and equity securities or securities convertible into equity securities, any of which may be senior to our common shares as to distributions and in liquidation, which could negatively affect the value of our common shares.

We have in the past, and may in the future as well, attempt to increase our capital resources by entering into debt or debt-like financing that is unsecured or secured by up to all of our assets, or by issuing additional debt or equity securities, which could include issuances of secured or unsecured commercial paper, medium-term notes, senior notes, subordinated notes, guarantees, preferred shares, hybrid securities, or securities convertible into or exchangeable for equity securities. In addition, the Preferred Shares issued in the concurrent note exchange rank senior to our common shares upon a liquidation, dissolution or winding up. The Preferred Shares also accrue cumulative dividends at a rate of 8% per annum, payable in additional Preferred Shares, which will increase the aggregate liquidation preference of the Preferred Shares over time. In the event of our liquidation, our lenders and holders of our debt and preferred securities would receive distributions of our available assets before distributions to the holders of our common shares. Because our decision to incur debt and issue securities in future offerings may be influenced by market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of our future offerings or debt financings. Further, market conditions could require us to accept less favorable terms for the issuance of our securities in the future.


Following the concurrent private placement, our officers and directors will beneficially own a significant percentage of our common shares and will be able to exert significant influence over matters subject to shareholder approval.

Upon the closing of this offering and the concurrent private placement, our officers and directors, including Dr. Bokhari, are expected to beneficially own approximately 31.4% of our outstanding common shares (assuming the exercise in full of the pre-funded warrants). As a result, these shareholders, acting together, may be able to significantly influence matters requiring shareholder approval, including the election of directors and approval of significant corporate transactions, and their interests may differ from the interests of other shareholders.

The market price of our common shares has been, and may continue to be, highly volatile, and you may lose all or a substantial part of your investment.

The market price of our common shares has fluctuated significantly and may continue to do so. For example, since the Share Consolidation became effective on October 12, 2026, the closing price of our common shares on Nasdaq has ranged from a high of $3.58 to a low of $1.64 per share, and on November 12, 2026, the closing price of our common shares was $1.72 per common share. Our public float is limited and trading volume in our common shares has historically been low and sporadic, which may exacerbate price volatility. The market price of our common shares may fluctuate as a result of a number of factors, many of which are beyond our control. As a result, you may be unable to resell your securities at or above the offering price.

We have no history of paying, and do not intend to pay, dividends on our common shares, so any returns will be substantially limited to the value of our common shares.

To date, we have not paid any dividends on our outstanding common shares. We currently intend to retain future earnings to finance the operation, development and expansion of our business. We do not anticipate paying cash dividends on our common shares in the foreseeable future. Any decision to pay dividends on our shares will be made at the discretion of our board of directors and will depend on our earnings, financial requirements and other conditions existing at such time. In addition, our ability to pay dividends on our common shares is, and may in the future be, limited by our indebtedness, by covenants of any current or future indebtedness we incur and by the rights of the holders of the Preferred Shares. As a result, you may not receive any return on an investment in our common shares unless you sell our common shares for a price greater than that which you paid for it.

Risks Related to the Pre-Funded Warrants

There is no public market for the pre-funded warrants being offered in this offering.

There is no established public trading market for the pre-funded warrants, and we do not expect a market to develop. In addition, we do not intend to apply to list the pre-funded warrants on any national securities exchange or other nationally recognized trading system. Without an active market, the liquidity of the pre-funded warrants will be limited.

Except as set forth in the pre-funded warrants, holders of the pre-funded warrants will have no rights as holders of our common shares until such holders exercise their pre-funded warrants and acquire our common shares.

Except as set forth in the pre-funded warrants, until holders of the pre-funded warrants acquire our common shares upon exercise thereof, such holders will have no rights with respect to the common shares underlying such pre-funded warrants, including voting rights. Upon exercise of the pre-funded warrants, the holders will be entitled to exercise the rights of a holder of our common shares only as to matters for which the record date occurs after the exercise date.

Significant holders or beneficial holders of our common shares may not be permitted to exercise the pre-funded warrants that they hold.

A holder of a pre-funded warrant will not be entitled to exercise any portion of the pre-funded warrant that would cause the aggregate number of our common shares beneficially owned by such holder (together with its affiliates and certain related parties) to exceed 4.99% (or, at the election of the holder, 9.99%) of the number of our common shares outstanding immediately after giving effect to the exercise. Such percentage ownership is determined in accordance with the terms of the pre-funded warrants. As a result, you may not be able to exercise your pre-funded warrants for our common shares at a time when it would be financially beneficial for you to do so. In such circumstance, you could seek to sell your pre-funded warrants to realize value, but you may be unable to do so in the absence of an established trading market.

We will not receive any meaningful additional funds upon the exercise of the pre-funded warrants.

Each pre-funded warrant may be exercised by paying a nominal exercise price of $0.0001 per share or by means of a cashless exercise. Accordingly, we will not receive any meaningful additional funds upon the exercise of the pre-funded warrants.


We believe that we will be treated as a U.S. corporation for U.S. federal income tax purposes.

As discussed more fully under "Certain Material U.S. Federal Income Tax Considerations," we believe that, pursuant to Section 7874 of the U.S. Internal Revenue Code of 1986, as amended (the "Code"), even though we are organized as a corporation under the laws of Ontario, Canada, the Company will be treated as a U.S. domestic corporation for all purposes of the Code. The Company will therefore be taxed as a U.S. domestic corporation for U.S. federal income tax purposes. As a result, the Company will be subject to U.S. federal income tax on its worldwide income. The Company is also subject to tax in Canada. It is unclear how the foreign tax credit rules under the Code will operate in certain circumstances, given our treatment as a U.S. domestic corporation for U.S. federal income tax purposes and the taxation of the Company in Canada. Accordingly, it is possible that we will be subject to double taxation with respect to all or part of our taxable income.

In addition, if the Company pays dividends to a Non-U.S. Holder, as defined in the discussion under the heading "Certain Material U.S. Federal Income Tax Considerations," it will be required to withhold U.S. income tax at the rate of 30%, or such lower rate as may be provided in an applicable income tax treaty. Each investor is urged to consult its own tax adviser regarding the U.S. federal income tax position of the Company and the tax consequences of holding our securities.           

The U.S. federal income tax treatment of the pre-funded warrants is uncertain.

As discussed more fully under "Certain Material U.S. Federal Income Tax Considerations," although the matter is not free from doubt, we intend to treat the pre-funded warrants as common shares for U.S. federal income tax purposes. This position is not binding on the U.S. Internal Revenue Service (the "IRS"), and the IRS may treat the pre-funded warrants differently. In that case, the amount, timing and character of income, gain or loss with respect to an investment in the pre-funded warrants could differ.


USE OF PROCEEDS

The gross proceeds to us from this offering will be approximately $3.0 million, excluding the proceeds, if any, from the exercise of the pre-funded warrants. We will receive nominal proceeds, if any, from the exercise of the pre-funded warrants. In addition, we expect to receive gross proceeds of approximately $1.25 million from the concurrent private placement. We will not receive any cash proceeds from the concurrent note exchange.

We currently intend to use the proceeds from this offering, together with the proceeds from the concurrent private placement, for working capital purposes, including to fund the continued development of our product candidates and/or the repayment of indebtedness.

We have broad discretion in determining how the proceeds of this offering will be used, and our discretion is not limited by the aforementioned possible uses. Our board of directors believes the flexibility in application of the proceeds is prudent. See the section entitled "Risk Factors-Risks Related to this Offering and to our Common Shares-Since we have broad discretion in how we use the proceeds from this offering, we may use the proceeds in ways with which you disagree."


DIVIDEND POLICY

We do not anticipate that we will declare or pay dividends in the foreseeable future on our common shares. Instead, we anticipate that all of our earnings will be used for the operation and growth of our business. Any future determination to declare cash dividends would be subject to the discretion of our board of directors and would depend upon various factors, including our results of operations, financial condition and liquidity requirements, restrictions that may be imposed by applicable law and our contracts and other factors deemed relevant by our board of directors. The Preferred Shares carry cumulative dividends at a rate of 8% per annum, payable in kind in additional Preferred Shares.


DESCRIPTION OF THE SECURITIES WE ARE OFFERING

Common Shares

Pursuant to this prospectus supplement, the Company is offering 97,973 common shares, as well as the pre-funded warrant shares. For information relating to the material terms of the Company's common shares, please see "Description of Share Capital" contained in Exhibit 4.1 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on March 25, 2026. The transfer agent and registrar for our common shares is Odyssey Trust Company.

Pre-Funded Warrants

The following summary of certain terms and provisions of the pre-funded warrants offered hereby is not complete. It is subject to, and qualified in its entirety by, the provisions of the form of pre-funded warrant. The form will be filed as an exhibit to a Current Report on Form 8-K that we will file with the SEC in connection with this offering and incorporated by reference into the registration statement of which this prospectus supplement forms a part. Prospective investors should carefully review the terms and provisions of the form of pre-funded warrant for a complete description of the terms and conditions of the pre-funded warrants.

Purpose. The pre-funded warrants are being offered, in lieu of common shares, to any investor whose purchase of common shares in this offering would otherwise result in such investor, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the investor, 9.99%) of our outstanding common shares immediately following the consummation of this offering.

Form. The pre-funded warrants will be issued in certificated form, registered in the name of the holder on a warrant register maintained by us.

Exercise Price. Each pre-funded warrant will have an exercise price of $0.0001 per common share. The aggregate exercise price of each pre-funded warrant, except for the nominal exercise price of $0.0001 per pre-funded warrant share, will be pre-funded to us upon issuance. Consequently, no additional consideration (other than the nominal exercise price) will be required to be paid by the holder to effect any exercise. The holder will not be entitled to the return or refund of all, or any portion, of the pre-paid aggregate exercise price under any circumstance or for any reason whatsoever, including in the event the pre-funded warrant is not exercised. The exercise price and the number of common shares issuable upon exercise of the pre-funded warrants are subject to appropriate adjustment in the event of certain share dividends and distributions, share subdivisions, share combinations (including by way of a share consolidation), reclassifications or similar events affecting our common shares.

Exercisability and Duration. The pre-funded warrants will be exercisable immediately upon issuance and may be exercised at any time until all of the pre-funded warrants are exercised in full. The pre-funded warrants do not expire. The pre-funded warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice. Except in the case of a cashless exercise as discussed below, the exercise notice must be accompanied by payment in full of the exercise price for the number of common shares purchased upon such exercise. No ink-original exercise notice or medallion guarantee is required. A holder will not be required to physically surrender a pre-funded warrant until it has been exercised in full.

Cashless Exercise. In lieu of making the cash payment otherwise contemplated to be made to us upon exercise in payment of the aggregate exercise price, a holder may elect at any time to exercise its pre-funded warrant, in whole or in part, by means of a "cashless exercise." In that case, the holder will receive upon such exercise the net number of common shares determined according to a formula set forth in the pre-funded warrant. In addition, a cashless exercise is mandatory for so long as any of the following conditions continues: (i) there is no effective registration statement registering the issuance of the pre-funded warrant shares to the holder; (ii) the prospectus contained in any such registration statement is not current or otherwise available for such issuance; or (iii) the amount of securities registered and remaining available for issuance under any such registration statement (including, if applicable, after giving effect to any limitation under General Instruction I.B.6 of Form S-3) is insufficient to cover the issuance of all of the pre-funded warrant shares subject to an exercise notice. Any exercise notice electing a cash exercise that is delivered while such a condition continues will be deemed to elect a cashless exercise, subject to a limited right of the holder to rescind the exercise notice if it had not received notice of such condition.

Delivery of Pre-Funded Warrant Shares. We will cause the pre-funded warrant shares to be delivered by the earlier of (i) two trading days and (ii) the number of trading days comprising the standard settlement period, in each case after the delivery of the exercise notice and receipt of the aggregate exercise price (other than in the case of a cashless exercise). If we fail to cause our transfer agent to deliver the pre-funded warrant shares by the applicable delivery date, the holder will have the right to rescind such exercise.


Exercise Limitation. We may not effect the exercise of any pre-funded warrant, and a holder will not be entitled to exercise any portion of any pre-funded warrant, that would cause the aggregate number of common shares beneficially owned by the holder (together with its affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates) to exceed 4.99% (or, at the election of the holder prior to the issuance of the pre-funded warrant, 9.99%) of the number of common shares outstanding immediately after giving effect to the exercise. Such percentage ownership is determined in accordance with the terms of the pre-funded warrants. A holder may increase or decrease this percentage upon notice to us, provided that the beneficial ownership limitation may in no event exceed 9.99%. Any increase will not be effective until the 61st day after such notice is delivered to us. In addition, in order to comply with Nasdaq’s shareholder approval requirements, we may not effect the exercise of any pre-funded warrant, and a holder will not be entitled to exercise any portion of any pre-funded warrant, that would cause (i) the holder (together with its affiliates and any other persons acting as a group together with the holder or any of the holder’s affiliates) to beneficially own more than 19.99% of the number of common shares outstanding immediately after giving effect to the exercise or (ii) a “change of control” of our company within the meaning of Nasdaq Listing Rule 5635(b), in each case unless and until we have obtained shareholder approval in accordance with Nasdaq rules. This limitation may not be waived, increased or otherwise modified by us or the holder, other than upon, and to the extent of, such shareholder approval, and applies to any successor holder or transferee of a pre-funded warrant.

Fractional Shares. No fractional common shares will be issued upon the exercise of the pre-funded warrants. As to any fraction of a share which the holder would otherwise be entitled to purchase upon such exercise, we will, at our election, either pay a cash adjustment in respect of such fraction in an amount equal to such fraction multiplied by the exercise price or round up to the next whole share.

Transferability. Subject to applicable laws, a pre-funded warrant may be transferred at the option of the holder upon surrender of the pre-funded warrant to us, together with the appropriate instruments of transfer and funds sufficient to pay any transfer taxes payable upon such transfer.

Trading Market. There is no established public trading market for the pre-funded warrants, and we do not expect a market to develop. We do not intend to apply for listing of the pre-funded warrants on any securities exchange or nationally recognized trading system. Without an active trading market, the liquidity of the pre-funded warrants will be limited. The common shares issuable upon exercise of the pre-funded warrants are listed on Nasdaq under the symbol "MDCX."

Rights as a Shareholder. Except as otherwise provided in the pre-funded warrants or by virtue of such holder's ownership of our common shares, the holders of the pre-funded warrants do not have the rights or privileges of holders of our common shares, including any voting rights, until they exercise their pre-funded warrants.

Subsequent Rights Offerings and Pro Rata Distributions. The holders of the pre-funded warrants are entitled to participate in certain pro rata rights offerings and distributions. If we grant, issue or sell any common share equivalents or rights to purchase shares, warrants, securities or other property pro rata to the record holders of our common shares, or declare or make any dividend or other distribution of our assets (or rights to acquire our assets) to holders of our common shares, each holder will participate to the same extent as if it had held the number of common shares acquirable upon complete exercise of its pre-funded warrants (without regard to any limitations on exercise). Such participation is subject to the beneficial ownership limitation, and any portion of such rights or distribution in excess of such limitation will be held in abeyance for the benefit of the holder until such time, if ever, as its right thereto would not result in the holder exceeding the beneficial ownership limitation.

Fundamental Transactions. The pre-funded warrants contain provisions that apply in the event of a fundamental transaction, as described in the pre-funded warrants. A fundamental transaction generally includes any of the following:

• any merger or consolidation with or into another person;

• the sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of our assets;

• the completion of a purchase offer, tender offer or exchange offer accepted by the holders of more than 50% of our outstanding common shares or more than 50% of the voting power of our common equity;

• any reclassification, reorganization or recapitalization of our common shares or any compulsory share exchange pursuant to which our common shares are effectively converted into or exchanged for other securities, cash or property; or

• the consummation of a share purchase agreement or other business combination with another person or group of persons whereby such other person or group acquires more than 50% of our outstanding common shares or more than 50% of the voting power of our common equity.

Upon any exercise of a pre-funded warrant following a fundamental transaction, the holder will have the right to receive, at the option of the holder (without regard to any limitation on exercise), for each pre-funded warrant share that would have been issuable upon such exercise immediately prior to the occurrence of such fundamental transaction, the number of common shares of the successor or acquiring corporation or of our company, if it is the surviving corporation, and any additional consideration receivable as a result of such fundamental transaction by a holder of the number of common shares for which the pre-funded warrant is exercisable immediately prior to such event. If holders of our common shares are given any choice as to the securities, cash or property to be received in a fundamental transaction, then the holder will be given the same choice as to the alternate consideration it receives upon any exercise of the pre-funded warrant following such fundamental transaction. We will cause any successor entity in a fundamental transaction in which we are not the survivor to assume all of our obligations under the pre-funded warrants. The pre-funded warrants do not entitle the holders to receive a cash payment based on the Black-Scholes value of the pre-funded warrants in connection with a fundamental transaction, and in no event will we be required to net cash settle an exercise of the pre-funded warrants.


Amendment and Waiver. The pre-funded warrants may be modified or amended, or the provisions thereof waived, with the written consent of our company and the respective holder.

Governing Law. The pre-funded warrants are governed by the laws of the State of New York.


DILUTION

If you invest in our securities in this offering, your ownership interest will be immediately diluted to the extent of the difference between the offering price per common share in this offering and the as adjusted net tangible book value per common share immediately after giving effect to this offering. For purposes of this discussion, the offering price per pre-funded warrant plus its exercise price is treated as equal to the offering price per common share. Our net tangible book value as of September 30, 2026 was approximately $(10.5) million, or $(5.67) per common share. We calculate net tangible book value per common share by dividing our net tangible book value, which is total tangible assets less total liabilities, by the number of our outstanding common shares.

After giving effect to the sale of 97,973 common shares in this offering at an offering price of $1.72 per share and pre-funded warrants to purchase up to 1,646,213 common shares at an offering price of $1.7199 per pre-funded warrant, and assuming the exercise in full of the pre-funded warrants, and after deducting estimated offering expenses payable by us (but without giving effect to the concurrent transactions or the sale of common shares under our at-the-market program after September 30, 2026), our as adjusted net tangible book value as of September 30, 2026 would have been approximately $(7.6) million, or $(2.07) per common share. This represents an immediate increase in net tangible book value of $3.57 per common share to existing shareholders and immediate dilution in as adjusted net tangible book value of $3.82 per common share to investors purchasing securities in this offering. The following table illustrates this calculation on a per common share basis:

Offering price per common share         $1.72  
Historical net tangible book value per common share as of September 30, 2026 $ (5.67 )      
Increase in net tangible book value per common share attributable to this offering $ 3.59        
As adjusted net tangible book value per common share as of September 30, 2026, after giving effect to this offering       $ (2.07 )
Dilution per common share to investors in this offering       $ 3.79  

The foregoing table does not take into account further dilution to new investors that could occur upon the exercise of outstanding options and warrants having a per share exercise price less than the offering price per share in this offering. It also does not take into account common shares issued after September 30, 2026, including the 112,985 common shares issued under our at-the-market program through November 12, 2026 and any common shares issuable under our at-the-market program in the future, and does not give effect to the concurrent note exchange, in which $10.5 million in principal amount of indebtedness under the A-1 Note was extinguished in exchange for 105,000 Preferred Shares, or to the issuance and sale of common shares in the concurrent private placement. Giving effect to these transactions would reduce the dilution to investors in this offering.

The foregoing table is based on 1,850,418 common shares outstanding as of September 30, 2026, and excludes, as of that date, the following:

• common shares issuable upon the exercise of outstanding options under the Incentive Plan and common shares available for future issuance under the Incentive Plan;

• 19,712 common shares issuable upon the exercise of the Company's Public Warrants, issued by the Company on November 14, 2024, at an exercise price of $232.00 per share;

• 324 common shares issuable upon the exercise of the Company's Regulation A Warrants, issued by the Company on March 10, 2025, at an exercise price of $140.00 per share;

• 45,200 common shares issuable upon the exercise of the Company's June 2030 Warrants, issued by the Company on June 2, 2025, at an exercise price of $155.00 per share; and

• 80,400 common shares issuable upon the exercise of the Company's Private Warrants, issued by the Company on December 10, 2025, at an exercise price of $100.00 per share.


To the extent that any outstanding warrants or options are exercised, new options or other equity awards are issued under our equity incentive plan, or we issue additional common shares in the future, there will be further dilution to new investors participating in this offering. In addition, we may choose to raise additional capital due to market conditions or strategic considerations. To the extent that additional capital is raised through the sale of securities, the issuance of those securities could result in further dilution to our shareholders


CERTAIN MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS

The following description is not intended to constitute a complete analysis of all tax considerations relating to the acquisition, ownership and disposition of our common shares and pre-funded warrants pursuant to this offering and (if applicable) pre-funded warrant shares upon the exercise of pre-funded warrants. You are urged to consult your own tax advisor concerning the tax considerations relevant to you having regard to your own circumstances, including tax considerations that may arise under the laws of any state, local, foreign or other taxing jurisdiction.

The following discussion describes certain material U.S. federal income tax consequences relating to the acquisition, ownership and disposition of our common shares, pre-funded warrants and pre-funded warrant shares, which we refer to collectively as our securities. This discussion applies to holders that purchase securities pursuant to this offering and hold such securities as capital assets within the meaning of Section 1221 of the Code (generally, assets held for investment purposes). This discussion is based on the Code, U.S. Treasury regulations promulgated thereunder ("Treasury Regulations") and administrative and judicial interpretations thereof, all as in effect on the date hereof and all of which are subject to change, possibly with retroactive effect.

This discussion does not address all of the U.S. federal income tax considerations that may be relevant to specific holders in light of their particular circumstances or to holders subject to special treatment under U.S. federal income tax law such as certain financial institutions, thrifts, insurance companies, broker-dealers and traders in securities or other persons that generally mark their securities to market for U.S. federal income tax purposes, tax-exempt entities, governmental organizations, retirement plans, regulated investment companies, real estate investment trusts, certain former citizens or residents of the United States, holders who hold securities as part of a "straddle", "hedge", "conversion transaction", "synthetic security" or integrated investment, holders whose "functional currency" (as defined in the Code) is not the U.S. dollar, corporations that accumulate earnings to avoid U.S. federal income tax, persons who acquired our shares through the exercise or cancellation of employee stock options or otherwise as compensation for their services, partnerships and other pass-through entities (or arrangements treated as a partnership for U.S. federal income tax purposes), and investors in such pass-through entities. In addition, this discussion does not address the tax treatment of partnerships (or entities or arrangements that are treated as partnerships for U.S. federal income tax purposes) or persons that hold our securities through such partnerships. If a partnership, including any entity or arrangement treated as a partnership for U.S. federal income tax purposes, holds our securities, the U.S. federal income tax treatment of a partner in such partnership will generally depend upon the status of the partner and the activities of the partnership. Such partners and partnerships are urged to consult their tax advisors regarding the tax consequences of the ownership and disposition of our securities. This discussion does not address any U.S. state or local or non-U.S. tax consequences or any U.S. federal estate, gift or alternative minimum tax consequences or the requirements of Section 451 of the Code with respect to conforming the timing of income accruals to financial statements. We have not requested, and will not request, a ruling from the IRS with respect to any of the U.S. federal income tax consequences described below, and as a result there can be no assurance that the IRS will not disagree with or challenge any of the conclusions described herein.

As used in this discussion, the term "U.S. Holder" means a beneficial owner of securities that is (1) an individual who is a citizen or resident alien of the United States for U.S. federal income tax purposes, (2) a corporation (or entity treated as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of the United States, any state thereof, or the District of Columbia, (3) an estate the income of which is subject to U.S. federal income tax regardless of its source or (4) a trust (x) with respect to which a court within the United States is able to exercise primary supervision over its administration and one or more U.S. persons have the authority to control all of its substantial decisions or (y) that has elected under applicable Treasury Regulations to be treated as a domestic trust for U.S. federal income tax purposes, and the term "Non-U.S. Holder" means a beneficial owner of our securities that is neither a U.S. Holder nor a partnership or an entity or arrangement treated as a partnership for U.S. federal income tax purposes.

The following discussion is for general information only and is not intended to be, nor should it be construed to be, legal or tax advice to any holder or prospective holder of securities and no opinion or representation with respect to the U.S. federal income tax consequences to any such holder or prospective holder is made. Persons considering an investment in securities are urged to consult their own tax advisors as to the particular tax consequences applicable to them relating to the purchase, ownership and disposition of securities, including the applicability of U.S. federal, state and local tax laws and non-U.S. tax laws.

Treatment as a Domestic Corporation for U.S. Federal Income Tax Purposes

Even though we are organized as a corporation existing under the laws of Ontario, as a result of our September 2023 business combination with SkinJect, Inc., we believe we are treated as a domestic corporation for U.S. federal income tax purposes pursuant to Section 7874 of the Code. As such, we will generally be subject to U.S. federal income tax as if we were organized under the laws of the United States or a state thereof. The remaining discussion contained in this "Certain Material U.S. Federal Income Tax Considerations" section assumes that we will be treated as a domestic corporation for all U.S. federal income tax purposes.


Treatment of Pre-Funded Warrants

Although the characterization of the pre-funded warrants for U.S. federal income tax purposes is not entirely clear, because the exercise price of the pre-funded warrants is nominal, we expect to treat the pre-funded warrants as common shares for U.S. federal income tax purposes. Accordingly, a holder of pre-funded warrants should generally be taxed in the same manner as a holder of common shares, as described below. No gain or loss should be recognized upon the exercise of a pre-funded warrant for cash, and upon exercise, the holding period of the pre-funded warrant shares received should include the holding period of the pre-funded warrant. Similarly, the tax basis of the pre-funded warrant shares received upon exercise of a pre-funded warrant should equal the tax basis of the pre-funded warrant, increased by the exercise price of $0.0001 per share. The balance of this discussion generally assumes that the characterization described above is respected for U.S. federal income tax purposes.

Our position with respect to the characterization of the pre-funded warrants is not binding on the IRS, and the IRS may treat the pre-funded warrants as warrants to acquire our common shares. In such case, the amount, timing and character of a holder's income, gain or loss with respect to an investment in the pre-funded warrants could change. In addition, the U.S. federal income tax treatment of a cashless exercise of pre-funded warrants into pre-funded warrant shares is unclear, and the tax consequences of a cashless exercise could differ from the consequences upon the exercise of a pre-funded warrant described in the preceding paragraph. Holders are urged to consult their own tax advisors regarding the characterization of the pre-funded warrants for U.S. federal income tax purposes, and the consequences to them of an investment in the pre-funded warrants based on their own particular facts and circumstances.

Tax Considerations Applicable to U.S. Holders

Distributions on Common Shares

If we pay distributions or make constructive distributions (other than certain distributions of our stock or rights to acquire our stock) to U.S. Holders, such distributions generally will constitute dividends for U.S. federal income tax purposes to the extent paid or deemed paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Distributions in excess of our current and accumulated earnings and profits will constitute a return of capital that will be applied against and reduce (but not below zero) the U.S. Holder's adjusted tax basis in our common shares. Any remaining excess will be treated as gain realized on the sale or other disposition of the common shares and will be treated as described under "-Dispositions of Common Shares and Pre-Funded Warrants" below.

Dividends we pay to a U.S. Holder that is taxable as a corporation will generally qualify for the dividends received deduction if the required holding period is satisfied. Dividends we pay to a non-corporate U.S. Holder will generally constitute "qualified dividends" which are subject to tax at preferential long-term capital gains rates provided certain holding period and other requirements are met. If the holding period requirements are not satisfied, a corporation may not be able to qualify for the dividends received deduction and would have taxable income equal to the entire dividend amount, and non-corporate holders may be subject to tax on such dividend at ordinary income tax rates instead of the preferential rates that apply to qualified dividend income.

If a U.S. Holder is subject to Canadian withholding tax on dividends paid on common shares to the U.S. Holder, the dividends will be considered U.S. source income, which could limit the ability of a U.S. Holder to claim a foreign tax credit for the Canadian withholding taxes imposed in respect of such a dividend. See "-Foreign Tax Credit Limitations" below.

Distributions on Pre-Funded Warrants

Holders of pre-funded warrants are entitled to participate in certain distributions on our common shares, as described above under "Description of the Securities We Are Offering-Pre-Funded Warrants-Subsequent Rights Offerings and Pro Rata Distributions". Consistent with our treatment of the pre-funded warrants as common shares, we expect any such distribution to be taxable to a U.S. Holder in the same manner as a distribution on our common shares, as described above under "-Distributions on Common Shares." However, under certain circumstances, a distribution may be held in abeyance for a U.S. Holder until a pre-funded warrant is exercised or the beneficial ownership limitation would not be exceeded, at which time the U.S. Holder would be entitled to receive the distribution. It is possible that such entitlement could cause the declaration of a distribution on our common shares to be currently taxable to U.S. Holders of pre-funded warrants, including under the principles of Section 305 of the Code, even though the holders will not receive the distribution until a future date. The treatment of distributions on pre-funded warrants is not entirely clear and U.S. Holders are urged to consult their own tax advisors regarding the U.S. federal income tax consequences of receiving distributions on the pre-funded warrants, including any distribution held in abeyance.


Dispositions of Common Shares and Pre-Funded Warrants

A U.S. Holder generally will recognize gain or loss on the sale, taxable exchange or other taxable disposition of our common shares or pre-funded warrants. Any such gain or loss will be capital gain or loss, and will be long-term capital gain or loss if the U.S. Holder's holding period for the common shares or pre-funded warrants so disposed of exceeds one year. The amount of gain or loss recognized will generally be equal to the difference between (1) the sum of the amount of cash and the fair market value of any property received in such disposition and (2) the U.S. Holder's adjusted tax basis in its common shares or pre-funded warrants so disposed of. A U.S. Holder's adjusted tax basis in its common shares or pre-funded warrants will generally equal the U.S. Holder's acquisition cost for such common shares (or, in the case of pre-funded warrant shares received upon exercise of a pre-funded warrant, the U.S. Holder's initial basis for such pre-funded warrant shares, as discussed above under "-Treatment of Pre-Funded Warrants"), less any prior distributions treated as a return of capital. Long-term capital gains recognized by non-corporate U.S. Holders are generally eligible for reduced rates of tax. If the U.S. Holder's holding period for the common shares or pre-funded warrants so disposed of is one year or less, any gain on a sale or other taxable disposition of the shares would be subject to short-term capital gain treatment and would be taxed at ordinary income tax rates. The deductibility of capital losses is subject to limitations.

To the extent a U.S. Holder pays any Canadian tax on a sale, exchange or disposition of our common shares or pre-funded warrants, a U.S. foreign tax credit may not be available. See "-Foreign Tax Credit Limitations" below.

Receipt of Foreign Currency

The gross amount of any payment in a currency other than U.S. dollars will be included by each U.S. Holder in income in a U.S. dollar amount calculated by reference to the exchange rate in effect on the day such U.S. Holder actually or constructively receives the payment in accordance with its regular method of accounting for U.S. federal income tax purposes regardless of whether the payment is in fact converted into U.S. dollars at that time. If the non-U.S. currency is converted into U.S. dollars on the date of the payment, the U.S. Holder should not be required to recognize any foreign currency gain or loss with respect to the receipt of non-U.S. currency. If, instead, the foreign currency is converted at a later date, any currency gains or losses resulting from the conversion of the foreign currency will be treated as U.S. source ordinary income or loss for U.S. foreign tax credit purposes. U.S. Holders are urged to consult their own U.S. tax advisors regarding the U.S. federal income tax consequences of receiving, owning, and disposing of foreign currency.

Foreign Tax Credit Limitations

Because the Company is subject to tax both as a U.S. domestic corporation and as a Canadian corporation, a U.S. Holder may pay, through withholding, Canadian tax, as well as U.S. federal income tax, with respect to dividends paid on its common shares or pre-funded warrants. For U.S. federal income tax purposes, a U.S. Holder may elect for any taxable year to receive either a credit or a deduction for foreign income taxes paid by the holder during the year. Complex limitations apply to the foreign tax credit, including a general limitation that the credit cannot exceed the proportionate share of a taxpayer's U.S. federal income tax that the taxpayer's foreign source taxable income bears to the taxpayer's worldwide taxable income. In applying this limitation, items of income and deduction must be classified, under complex rules, as either foreign source or U.S. source.

The status of the Company as a U.S. domestic corporation for U.S. federal income tax purposes will cause dividends paid by the Company to be treated as U.S. source rather than foreign source income for this purpose. As a result, a foreign tax credit may be unavailable for any Canadian tax paid on dividends received from the Company. Similarly, to the extent a sale or disposition of common shares or pre-funded warrants by a U.S. Holder results in Canadian tax payable by the U.S. Holder (for example, because the common shares or pre-funded warrants constitute taxable Canadian property within the meaning of the Income Tax Act (Canada)), a U.S. foreign tax credit may be unavailable to the U.S. Holder for such Canadian tax. In each case, however, the U.S. Holder may be able to take a deduction for the U.S. Holder's Canadian tax paid, provided that the U.S. Holder has not elected to credit other foreign taxes during the same taxable year. The foreign tax credit rules are complex, and each U.S. Holder is urged to consult its own tax advisor regarding these rules.

Additional Tax on Net Investment Income

U.S. Holders that are individuals, estates or trusts are required to pay an additional 3.8% tax on the lesser of (1) the U.S. Holder's "net investment income" for the relevant taxable year and (2) the excess of the U.S. Holder's modified adjusted gross income for the taxable year over a certain threshold. A U.S. Holder's "net investment income" generally includes, among other things, dividends and net gains from disposition of property (other than property held in the ordinary course of the conduct of a trade or business).


Accordingly, dividends on and capital gain from the sale, exchange or other taxable disposition of common shares and pre-funded warrants may be subject to this additional tax. U.S. Holders are urged to consult their own tax advisors regarding the additional tax on passive income.

Information Reporting and Backup Withholding

In general, information reporting requirements may apply to distributions paid to a U.S. Holder and to the proceeds of the sale or other disposition of our common shares and pre-funded warrants, unless the U.S. Holder is an exempt recipient. Backup withholding may apply to such payments if a U.S. Holder does not establish, in the manner provided by law, an exemption from backup withholding, or fails to provide a correct taxpayer identification number or make any other required certifications.

Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules will be allowed as a refund or credit against U.S. federal income tax liability, provided that the required information is timely furnished to the IRS. U.S. Holders are urged to consult their own tax advisors regarding their qualification for an exemption from backup withholding and the procedures for obtaining such an exemption.

Tax Considerations Applicable to Non-U.S. Holders

Distributions on Common Shares

Distributions of cash or property that we pay in respect of our common shares will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). Subject to the discussions below under "-U.S. Trade or Business Income," "-Information Reporting and Backup Withholding" and "-FATCA," Non-U.S. Holders generally will be subject to U.S. federal withholding tax at a 30% rate, or at a reduced rate prescribed by an applicable income tax treaty, on any dividends received in respect of our common shares. If the amount of the distribution exceeds our current and accumulated earnings and profits, such excess first will be treated as a return of capital to the extent of the Non-U.S. Holder's tax basis in our common shares, and thereafter will be treated as capital gain and will be treated as described below under "-Dispositions of Common Shares and Pre-Funded Warrants." However, except to the extent that we elect (or the paying agent or other intermediary through which a Non-U.S. Holder holds its common shares elects) otherwise, we (or the intermediary) must generally withhold at the applicable rate on the entire distribution, in which case the Non-U.S. Holder would be entitled to a refund from the IRS for the withholding tax on the portion, if any, of the distribution that exceeded our current and accumulated earnings and profits.

In order to obtain a reduced rate of U.S. federal withholding tax under an applicable income tax treaty, Non-U.S. Holders will be required to provide a properly executed IRS Form W-8BEN or Form W-8BEN-E (or, in each case, a successor form) certifying the Non-U.S. Holder's entitlement to benefits under such treaty. If a Non-U.S. Holder is eligible for a reduced rate of U.S. federal withholding tax under an income tax treaty, it may obtain a refund or credit of any excess amounts withheld by filing an appropriate claim for a refund with the IRS. Non-U.S. Holders are urged to consult their own tax advisors regarding their possible entitlement to benefits under an applicable income tax treaty.

Distributions on Pre-Funded Warrants

Holders of pre-funded warrants are entitled to participate in certain distributions on our common shares, as described above under "Description of the Securities We Are Offering-Pre-Funded Warrants-Subsequent Rights Offerings and Pro Rata Distributions". We expect to treat any such distributions in the same manner as distributions on our common shares. As a result, subject to the discussions below under "-U.S. Trade or Business Income," "-Information Reporting and Backup Withholding" and "-FATCA," Non-U.S. Holders generally will be subject to U.S. federal withholding tax at a 30% rate, or at a reduced rate prescribed by an applicable income tax treaty, on such distributions to the extent treated as dividends, as described above under "-Distributions on Common Shares." A distribution held in abeyance under the beneficial ownership limitation, as described above under "-U.S. Holders-Distributions on Pre-Funded Warrants," could be treated as currently paid, and therefore subject to withholding, even though the Non-U.S. Holder will not receive the distribution until a future date. However, the treatment of distributions on pre-funded warrants is not entirely clear and Non-U.S. Holders are urged to consult their own tax advisors regarding the U.S. federal income tax consequences of receiving distributions on the pre-funded warrants.

In order to obtain a reduced rate of U.S. federal withholding tax under an applicable income tax treaty, Non-U.S. Holders will be required to provide a properly executed IRS Form W-8BEN or Form W-8BEN-E (or, in each case, a successor form) certifying the Non-U.S. Holder's entitlement to benefits under such treaty. If a Non-U.S. Holder is eligible for a reduced rate of U.S. federal withholding tax under an income tax treaty, or otherwise determines that we over-withheld from distributions to the Non-U.S. Holder, it may obtain a refund or credit of any excess amounts withheld by filing an appropriate claim for a refund with the IRS. Non-U.S. Holders are urged to consult their own tax advisors regarding their possible entitlement to benefits under an applicable income tax treaty.


Dispositions of Common Shares or Pre-Funded Warrants

Subject to the discussions below under "-U.S. Trade or Business Income," "-Information Reporting and Backup Withholding" and "-FATCA," Non-U.S. Holders generally will not be subject to U.S. federal income or withholding tax in respect of any gain on a sale, exchange or other taxable disposition of our common shares or pre-funded warrants unless:

• the gain is U.S. trade or business income (as defined below), in which case, such gain will be taxed as described in "-U.S. Trade or Business Income" below;

• the Non-U.S. Holder is an individual who is present in the United States for 183 or more days in the taxable year of the disposition and certain other conditions are met, in which case the Non-U.S. Holder will be subject to U.S. federal income tax at a rate of 30% (or a reduced rate under an applicable income tax treaty) on the amount by which certain capital gains allocable to U.S. sources exceed certain capital losses allocable to U.S. sources, provided the Non-U.S. Holder has timely filed its U.S. federal income tax return with respect to such losses; or

• we are or have been a "United States real property holding corporation" (a "USRPHC") under Section 897 of the Code at any time during the shorter of the five-year period ending on the date of the disposition and the Non-U.S. Holder's holding period for such common shares or pre-funded warrants, in which case, subject to the exception set forth in the last sentence of the next paragraph, such gain will be subject to U.S. federal income tax as described in "-U.S. Trade or Business Income" below.

In general, a corporation is a USRPHC if the fair market value of its "United States real property interests" equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests and its other assets used or held for use in a trade or business. We believe that we are not currently, and we do not anticipate becoming in the future, a USRPHC for U.S. federal income tax purposes. In the event that we are determined to be a USRPHC, gain arising from the sale, exchange or other taxable disposition of common shares or pre-funded warrants by a Non-U.S. Holder will, nonetheless, not be subject to tax as U.S. trade or business income if our common shares are "regularly traded" (as defined by applicable Treasury Regulations) on an established securities market unless the Non-U.S. Holder's holdings (direct and indirect, taking into account certain constructive ownership rules) exceed certain thresholds.

U.S. Trade or Business Income

For purposes of this discussion, dividends paid in respect of common shares or pre-funded warrants and gain on the sale, exchange or other taxable disposition of common shares or pre-funded warrants will be considered to be "U.S. trade or business income" if (A)(i) such dividends or gain is effectively connected with the Non-U.S. Holder's conduct of a trade or business within the United States and (ii) the Non-U.S. Holder is eligible for the benefits of an applicable income tax treaty and such treaty requires that such dividends or gain is attributable to a permanent establishment (or, if the Non-U.S. Holder is an individual, a fixed base) that the Non-U.S. Holder maintains in the United States or (B) with respect to gain, we are or have been a USRPHC at any time during the shorter of the five-year period ending on the date of the disposition of our common shares or pre-funded warrants and the Non-U.S. Holder's holding period for our common shares or pre-funded warrants (subject to the exception set forth above in the last sentence of the second paragraph of "-Dispositions of Common Shares and Pre-Funded Warrants"). Generally, a Non-U.S. Holder's U.S. trade or business income is not subject to U.S. federal withholding tax (provided that the Non-U.S. Holder complies with applicable certification and disclosure requirements, including providing a properly executed IRS Form W-8ECI (or successor form)); instead, the Non-U.S. Holder is subject to U.S. federal income tax on a net basis at regular U.S. federal income tax rates (generally in the same manner as a U.S. person) on the Non-U.S. Holder's U.S. trade or business income. Any U.S. trade or business income received by a corporate Non-U.S. Holder may also be subject to a "branch profits tax" at a 30% rate, or at a lower rate prescribed by an applicable income tax treaty.

Information Reporting and Backup Withholding

We must annually report to the IRS and to each Non-U.S. Holder any dividends paid in respect of our common shares or pre-funded warrants that is subject to U.S. federal withholding tax or that is exempt from such withholding tax pursuant to an income tax treaty. Copies of these information returns may also be made available under the provisions of a specific treaty or agreement to the tax authorities of the country in which a Non-U.S. Holder resides or is established. Under certain circumstances, the Code imposes a backup withholding obligation on certain reportable payments. Dividends paid to a Non-U.S. Holder will generally be exempt from backup withholding if the Non-U.S. Holder certifies its non-U.S. status by providing a properly executed IRS Form W-8BEN, Form W-8BEN-E or Form W-8ECI (or, in each case, a successor form) or otherwise establish an exemption, and the applicable withholding agent does not have actual knowledge or reason to know that the Non-U.S. Holder is a U.S. person or that the conditions of such other exemption are not, in fact, satisfied.


The payment of the proceeds from a Non-U.S. Holder's sale, exchange or other taxable disposition of our common shares or pre-funded warrants to or through the U.S. office of any broker (U.S. or non-U.S.) will be subject to information reporting and, depending on the circumstances, backup withholding unless the Non-U.S. Holder certifies as to its non-U.S. status under penalties of perjury by providing the certification described above to the broker or otherwise establish an exemption, and the broker does not have actual knowledge or reason to know that the Non-U.S. Holder is a U.S. person or that the conditions of any other exemption are not, in fact, satisfied. The payment of proceeds from a Non-U.S. Holder's sale, exchange or other taxable disposition of our common shares or pre-funded warrants to or through a non-U.S. office of a non-U.S. broker will not be subject to information reporting or backup withholding unless the non-U.S. broker has certain types of relationships with the United States (a "U.S. related financial intermediary"). In the case of the payment of proceeds from a Non-U.S. Holder's sale, exchange or other taxable disposition of our common shares or pre-funded warrants to or through a non-U.S. office of a broker that is either a U.S. person or a U.S. related financial intermediary, information reporting and, depending on the circumstances, backup withholding will apply on the payment unless the broker has documentary evidence, such as the certifications described above, in its files certifying that the Non-U.S. Holder is not a U.S. person and the broker has no knowledge to the contrary. Non-U.S. Holders are urged to consult their own tax advisors regarding the application of information reporting and backup withholding in light of their particular circumstances.

Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules from a payment to a Non-U.S. Holder will be refunded or credited against the Non-U.S. Holder's U.S. federal income tax liability, if any, provided that the required information is timely furnished to the IRS.

FATCA

Pursuant to Sections 1471 through 1474 of the Code, commonly referred to as the Foreign Account Tax Compliance Act ("FATCA"), "foreign financial institutions" and "non-financial foreign entities" (each as defined in the Code) that do not otherwise qualify for an exemption must comply with information reporting rules with respect to their U.S. account holders and investors or be subject to a withholding tax on certain types of U.S.-source payments made to them (whether received as a beneficial owner or as an intermediary for another party).

More specifically, a foreign financial institution or non-financial foreign entity that does not comply with the FATCA reporting requirements or otherwise qualify for an exemption will generally be subject to a 30% withholding tax with respect to any "withholdable payments." For this purpose, withholdable payments generally include dividends on, or (subject to the proposed Treasury Regulations discussed below) gross proceeds from the disposition of, our common shares or pre-funded warrants paid to a foreign financial institution or non-financial foreign entity. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules.

Withholding under FATCA currently applies to dividends paid in respect of our common shares and pre-funded warrants. Proposed Treasury Regulations, the preamble to which state that they can be relied upon until final Treasury Regulations are issued, exempt from FATCA withholding gross proceeds from the dispositions of stock. To prevent withholding on dividends, Non-U.S. Holders may be required to provide the Company (or its withholding agents) with applicable tax forms or other information. Non-U.S. Holders are urged to consult with their own tax advisors regarding the effect, if any, of FATCA to them based on their particular circumstances.


PLAN OF DISTRIBUTION

We are offering 97,973 common shares and pre-funded warrants to purchase up to 1,646,213 common shares directly to certain investors pursuant to this prospectus supplement and the base prospectus. We have entered into the securities purchase agreement directly with each of the investors in connection with this offering, and we will only sell to investors who have entered into the securities purchase agreement. The form of securities purchase agreement and the form of pre-funded warrant will be included as exhibits to a Current Report on Form 8-K that we will file with the SEC and that will be incorporated by reference into the registration statement of which this prospectus supplement forms a part.

The offering price of the securities offered hereby was determined based on negotiations between us and the investors. It is equal to the closing price of our common shares on Nasdaq on November 12, 2026 (or, in the case of the pre-funded warrants, such closing price less $0.0001).

We are not using a placement agent, underwriter, broker or dealer in connection with this offering, and we will not pay any underwriting discounts, commissions, placement agent fees or finders' fees in connection with the sale of the securities offered hereby.

We have engaged Maxim Group LLC ("Maxim") to advise us in connection with this offering and have agreed to pay Maxim a cash fee of $200,000 in connection therewith and to reimburse Maxim for certain of its expenses. Maxim also acts as one of our sales agents under our at-the-market program and has in the past provided, and may in the future provide, investment banking and other services to us, for which it has received and may receive customary fees.

We expect to deliver the common shares being offered pursuant to this prospectus supplement and the base prospectus through the Deposit or Withdrawal at Custodian system of The Depository Trust Company, and the pre-funded warrants in certificated form, on or about November 13, 2026, subject to the satisfaction of customary closing conditions. There is no arrangement for funds to be received in an escrow, trust or similar arrangement.

The securities purchase agreement contains customary representations, warranties and covenants of us and the investors. We have agreed to indemnify the investors and certain related parties against certain losses and liabilities arising out of or relating to, among other things, any breach of our representations, warranties or covenants under the securities purchase agreement. This indemnity also covers any action instituted against such persons by us or by any of our shareholders who is not an affiliate of such person arising out of the transactions contemplated by the securities purchase agreement. In addition, we have agreed to use the proceeds as described under "Use of Proceeds" and to use reasonable best efforts to maintain the listing of our common shares on Nasdaq. The investors' obligation to close is subject to customary conditions, including our receipt of not less than $1.1 million in gross cash proceeds from the concurrent private placement at a price per share not less than $1.72. Each investor may terminate its obligations under the securities purchase agreement if the closing has not occurred on or before the fifth trading day following the date of the securities purchase agreement.

In addition to the total expenses of this offering payable by us, which consist of legal, accounting, printing, transfer agent and other miscellaneous fees and expenses, we have also agreed to pay all transfer agent fees, stamp taxes and other taxes and duties levied in connection with the delivery of the securities to the investors.

We are subject to the applicable provisions of the Exchange Act and the rules and regulations under the Exchange Act, including Regulation M, which may limit the timing of purchases and sales of our common shares by us and our affiliated purchasers while this offering is ongoing.

This prospectus supplement and the base prospectus may be made available in electronic format on a website maintained by us. Other than this prospectus supplement and the base prospectus in electronic format, the information on our website is not part of this prospectus supplement, the base prospectus or the registration statement of which this prospectus supplement forms a part.

The foregoing does not purport to be a complete statement of the terms and conditions of the securities purchase agreement or the pre-funded warrants.

Our common shares are listed on Nasdaq under the symbol "MDCX," and our Public Warrants are listed on Nasdaq under the symbol "MDCXW." We do not intend to list the pre-funded warrants on any securities exchange or nationally recognized trading system. The transfer agent and registrar for our common shares is Odyssey Trust Company.

Other than in the United States, no action has been or will be taken by us that would permit a public offering of the securities offered by this prospectus supplement in any jurisdiction where action for that purpose is required. The securities offered by this prospectus supplement may not be offered or sold, directly or indirectly, nor may this prospectus supplement or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus supplement comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus supplement. This prospectus supplement does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus supplement in any jurisdiction in which such an offer or a solicitation is unlawful.


LEGAL MATTERS

The validity of the issuance of the common shares offered hereby (including the pre-funded warrant shares) and certain other legal matters as to Canadian law will be passed upon for us by Bennett Jones LLP, Toronto, Canada. The validity of the pre-funded warrants offered hereby and certain other legal matters governed by U.S. law will be passed upon for us by Paul, Weiss, Rifkind, Wharton & Garrison LLP, New York, New York.

EXPERTS

No expert or counsel named in this prospectus supplement as having prepared or certified any part of this prospectus supplement or having given an opinion upon the validity of the securities being registered or upon other legal matters in connection with the registration or offering of the securities was employed on a contingency basis or had, or is to receive, in connection with the offering, a substantial interest, directly or indirectly, in the Company or its subsidiaries. Nor was any such person connected with the Company or any of its subsidiaries as a promoter, managing or principal underwriters, voting trustee, director, officer or employee.

The consolidated financial statements of Medicus Pharma Ltd. and subsidiaries (the Company) as of December 31, 2025, and for the year ended December 31, 2025, have been incorporated by reference herein in reliance upon the report of KPMG LLP, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing. The audit report covering the December 31, 2025 consolidated financial statements contains an explanatory paragraph that states that the Company has incurred significant operating losses and cash outflows from operating activities that raise substantial doubt about its ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty.

The consolidated balance sheets of Medicus Pharma Ltd. and Subsidiaries as of December 31, 2024, and the related  consolidated statements of operations and comprehensive loss, stockholders' equity, and cash flows for the year then ended, have been audited by EisnerAmper LLP, independent registered public accounting firm, as stated in their report which is incorporated by reference, which report includes an explanatory paragraph about the existence of substantial doubt concerning the Company's ability to continue as a going concern. Such financial statements have been incorporated by reference in reliance on the report of such firm given upon their authority as experts in accounting and auditing.

WHERE YOU CAN FIND MORE INFORMATION

We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available on the SEC's website at http://www.sec.gov. We also make available free of charge on our website at http://www.medicuspharma.com all materials that we file electronically with the SEC.

As permitted by SEC rules, this prospectus supplement does not contain all of the information we have included in the registration statement and the accompanying exhibits and schedules we file with the SEC. You may refer to the registration statement, exhibits and schedules for more information about us and the securities. The registration statement, exhibits and schedules are available through the SEC's website.

INFORMATION INCORPORATED BY REFERENCE

In this prospectus supplement, we “incorporate by reference” certain information that is filed with the SEC, which means that we can disclose important information to you by referring you to that information. The information we incorporate by reference is an important part of this prospectus supplement, and later information that we file with the SEC will automatically update and supersede this information. The following documents have been filed by us with the SEC and are incorporated by reference into this prospectus supplement:


  • our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the SEC on March 25, 2026, and the related Amendment No. 1 to our Annual Report on Form 10-K/A, as filed with the SEC on April 29, 2026;

  • our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, as filed with the SEC on May 14, 2026;

  • our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, as filed with the SEC on August 12, 2026;

  • our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026, as filed with the SEC on November 6, 2026;

  • our Current Reports on Form 8-K, as filed with the SEC on March 6, 2026, April 24, 2026, May 27, 2026, June 4, 2026, September 3, 2026, September 11, 2026, September 14, 2026, October 7, 2026, October 16, 2026 and October 23, 2026 (other than any portions thereof furnished and not filed); and

  • the description of our securities contained in Exhibit 4.1 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on March 25, 2026, and any amendment or report filed for the purpose of updating such description.

Additionally, all documents and reports that we file with the SEC (other than any portion of such filings that are furnished under applicable SEC rules rather than filed) under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act from the date of this prospectus supplement until the completion of the offering under this prospectus supplement shall be deemed to be incorporated in this prospectus supplement by reference. The information contained on or accessible through our website (http://www.medicuspharma.com) is not incorporated into this prospectus supplement.

You may request a copy of these filings, other than an exhibit to these filings unless we have specifically included or incorporated that exhibit by reference into the filing, from the SEC as described under “Where You Can Find More Information” or, at no cost, by writing or telephoning the Company at the following address:

Medicus Pharma Ltd.

Attention: Corporate Secretary

300 Conshohocken State Rd., Suite 200

W. Conshohocken, PA 19428

(610) 636-0184

madesso@medicuspharma.com

You should rely only on the information contained or incorporated by reference in this prospectus supplement. We have not authorized any person, including any salesman or broker, to provide information other than that provided in this prospectus supplement. We have not authorized anyone to provide you with different information. We do not take responsibility for, and can provide no assurance as to the reliability of, any information that others may give you. We are not making an offer of the securities in any jurisdiction where the offer is not permitted. You should not assume that the information in this prospectus supplement or any documents incorporated by reference is accurate as of any date other than the date of the applicable document.

Any statement contained in a document incorporated or deemed to be incorporated by reference into this prospectus supplement will be deemed to be modified or superseded for purposes of this prospectus supplement to the extent that a statement contained in this prospectus supplement or any other subsequently filed document that is deemed to be incorporated by reference into this prospectus supplement modifies or supersedes the statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus supplement.


The information in this prospectus is not complete and may be changed. We may not sell these securities until the Securities and Exchange Commission declares our registration statement effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

Subject to completion, dated December 29, 2025

 

PROSPECTUS

$100,000,000

Common Shares
Preferred Shares

Subscription Rights

Units

Warrants

By this prospectus and an accompanying prospectus supplement, we may from time to time offer and sell, in one or more offerings, up to $100,000,000 in any combination of common shares, preferred shares, subscription rights, units or warrants.

We will provide you with more specific terms of these securities in one or more supplements to this prospectus. We may also authorize one or more free-writing prospectuses to be provided to you in connection with these offerings. You should read this prospectus and any applicable prospectus supplement or free writing prospectus, as well as any documents incorporated by reference carefully before you invest.

We may offer these securities from time to time in amounts, at prices and on other terms to be determined at the time of offering. We may offer and sell these securities to or through underwriters, dealers or agents, or directly to investors, on a continuous or delayed basis. The supplements to this prospectus will provide the specific terms of the plan of distribution. The price to the public of such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement.

Our common shares and public warrants, with an exercise price of $4.64 and expiration date of November 15, 2029 (the “Public Warrants”) are listed on the Nasdaq Capital Market (“Nasdaq”) under the symbols “MDCX” and “MDCXW”, respectively. On December 26, 2025, the closing price of our common shares as reported by Nasdaq was $1.57 per share and the closing price of our Public Warrants as reported by Nasdaq was $0.81 per Public Warrant.

As of December 22, 2025, the aggregate market value of our outstanding common shares held by non-affiliates was approximately $46 million, which we calculated based on 25,114,144 outstanding common shares as of December 22, 2025, of which 18,643,329 shares were held by non-affiliates, and a price per share of $2.47, which was the closing price of our common shares on October 30, 2025. We have not offered or sold any securities pursuant to General Instruction I.B.6 of Form S-3 during the prior 12-calendar-month period that ends on and includes the date of this prospectus. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell, pursuant to the registration statement of which this prospectus forms a part, securities with a value exceeding one-third of the aggregate market value of our outstanding common shares held by non-affiliates in any 12-month period, so long as the aggregate market value of our outstanding common shares held by non-affiliates remains below $75.0 million.

An investment in our securities involves a high degree of risk. See "Risk Factors" on page 10 of this prospectus for more information on these risks.

Neither the Securities and Exchange Commission (the "SEC") nor any state securities commission has approved or disapproved of these securities, or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

The date of this prospectus is                        , 2025.


TABLE OF CONTENTS


  Page
   
ABOUT THIS PROSPECTUS 1
   
TRADEMARKS, TRADE NAMES AND SERVICE MARKS 2
   
MARKET, INDUSTRY AND OTHER DATA 3
   
CAUTIONARY NOTE CONCERNING FORWARD-LOOKING STATEMENTS 4
   
OUR BUSINESS 6
   
RISK FACTORS 10
   
USE OF PROCEEDS 11
   
DILUTION 12
   
DESCRIPTION OF THE SECURITIES THAT MAY BE OFFERED 13
   
PLAN OF DISTRIBUTION 17
   
LEGAL MATTERS 21
   
EXPERTS 21
   
WHERE YOU CAN FIND MORE INFORMATION 21
   
INFORMATION INCORPORATED BY REFERENCE 21


ABOUT THIS PROSPECTUS

This prospectus is part of a registration statement filed with the SEC using a "shelf" registration process. Under this shelf process, we may sell the securities described in this prospectus in one or more primary offerings, up to the maximum aggregate dollar amount $100,000,000.

This prospectus provides you with a general description of the securities which may be offered. Each time we offer securities for sale, we will provide a prospectus supplement that contains specific information about the terms of that offering. Any prospectus supplement may also add or update information contained in this prospectus. You should read both this prospectus and any prospectus supplement together with additional information described below under "Where You Can Find More Information" and "Information Incorporated by Reference."

The registration statement that contains this prospectus (including the exhibits thereto) contains additional important information about us and the securities we may offer under this prospectus. Specifically, we have filed certain legal documents that establish the terms of the securities offered by this prospectus as exhibits to the registration statement. We will file certain other legal documents that establish the terms of the securities offered by this prospectus as exhibits to reports we file with the SEC. You may obtain copies of that registration statement and the other reports and documents referenced herein as described below under the heading "Where You Can Find More Information."

You should rely only on the information contained or incorporated by reference in this prospectus and in any prospectus supplement. We have not authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not making offers to sell or solicitations to buy the securities in any jurisdiction in which an offer or solicitation is not authorized or in which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. You should not assume that the information in this prospectus or any prospectus supplement, as well as the information we file or previously filed with the SEC that we incorporate by reference in this prospectus or any prospectus supplement, is accurate as of any date other than its respective date. Our business, financial condition, results of operations and prospects may have changed since those dates.

In this prospectus, unless otherwise indicated or the context otherwise requires, references to "we," "us," "our," the "Company" and "Medicus" refer to the consolidated operations of Medicus Pharma Ltd. and its subsidiaries.


TRADEMARKS, TRADE NAMES AND SERVICE MARKS

This prospectus, including the information incorporated by reference herein, contains references to trademarks and service marks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus and documents incorporated by reference in this prospectus may appear without the ® or ™ symbols, but such references are not intended to indicate, in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. We do not intend our use or display of other companies' trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of them by, any other companies.


MARKET, INDUSTRY AND OTHER DATA

This prospectus, including the information incorporated by reference herein, contains estimates, projections and other information concerning our industry, our business, and the markets for certain products and services, including data regarding the estimated size of those markets and their projected growth rates. Information that is based on estimates, forecasts, projections or similar methodologies is based on a number of assumptions and is inherently subject to uncertainties, including those described in "Risk Factors" and elsewhere in this prospectus and documents incorporated by reference in this prospectus, and actual events or circumstances may differ materially from events and circumstances reflected in this information. You are cautioned not to give undue weight to such estimates, projections and other information.


CAUTIONARY NOTE CONCERNING FORWARD-LOOKING STATEMENTS

This prospectus and the documents incorporated by reference herein include forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included or incorporated by reference in this prospectus regarding our strategy, future operations, regulatory process, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. The words "believe", "anticipate", "intend", "expect", "target", "goal", "estimate", "plan", "assume", "may", "will", "predict", "project", "would", "could" and similar expressions or the negative of such terms are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

The forward-looking statements included or incorporated by reference in this prospectus include, but are not limited to, statements about:

  • our financial results, including our ability to continue as a going concern, generate earnings and achieve and sustain profitability, which may vary significantly from forecasts and from period to period;

  • the progress, timing and completion of our research, development and preclinical studies and clinical trials for our products and product candidates;

  • our ability to successfully integrate Antev Limited ("Antev") into our business and operations, successfully develop Teverelix (as defined herein) and realize the benefits currently anticipated from the transaction;

  • our ability to market, commercialize, achieve market acceptance for and sell our products and product candidates;

  • our ability to develop, manage and maintain our direct sales and marketing organizations;

  • our estimates regarding anticipated operating losses, future revenues, capital requirements and our needs for additional financing;

  • market risks regarding consolidation in the healthcare, pharmaceutical and biotech/life sciences industry;

  • the willingness of healthcare providers to purchase our products if coverage, reimbursement and pricing from third party payors for procedures using our products significantly declines;

  • our ability to adequately protect our intellectual property and operate our business without infringing upon the intellectual property rights of others;

  • the market price of our securities may be volatile and fluctuate substantially, which could cause the value of your investment to decline;

  • the fact that product quality issues or product defects may harm our business;

  • any product liability claims; and

  • the regulatory, legal and certain operating risks that our operations subject us to.

We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this prospectus and in the documents incorporated by reference herein, particularly the factors described in the "Risk Factors" section of this prospectus and the factors under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024 (the "Annual Report"), incorporated by reference herein, that could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make.


You should read this prospectus and the documents incorporated by reference herein, completely and with the understanding that our actual future results may be materially different from what we expect. We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are subject to risks, uncertainties and assumptions about us, including those listed in the section of this prospectus entitled "Risk Factors", in the section entitled "Risk Factors" in our Annual Report and in our other filings which are incorporated by reference herein.

Any forward-looking statement made by us is based on information available to us at the time of such statement and speaks only as of the date on which it was made. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.


OUR BUSINESS

This is only a summary and may not contain all the information that is important to you. You should carefully read both this prospectus and any accompanying prospectus supplement and any other offering materials, together with the additional information described under the heading "Where You Can Find More Information."

The Company

We are a clinical-stage, multi-strategy, life science and biotech company focused on investing in and  accelerating the clinical development programs of novel and disruptive therapeutic assets. Currently, we are  developing two products, SkinJectTM ("SkinJectTM"), with an indication for basal cell carcinoma, and Teverelix trifluoroacetate ("Teverelix", and together with SkinJectTM, the "Products").

Through our wholly owned subsidiary, SkinJect, Inc. ("SkinJect"), we focus on the development of our in-licensed drug device combination product using novel dissolvable microneedle arrays for the treatment of non-melanoma skin cancers. Our combination product candidate is a doxorubicin tip-loaded microneedle arrays ("D-MNA") filed with the Food and Drug Administration (the "FDA") under an Investigational New Drug Application and is regulated by the Center for Drug Evaluation and Registration ("CDER"), Oncology Division.

Prior to the Company's acquisition of SkinJect, our business was undertaken by SkinJect as a stand-alone entity. References to our business as conducted at a date prior to the completion of the Business Combination (as defined below) relate to the business undertakings of SkinJect.

For information on the Business Combination, see "Corporate History and Information."

We are subject to significant risks and uncertainties, including those related to our limited operating history, our lack of historical earnings, and the fact that the Products are novel technologies for which regulatory approval might not be achieved. For more information, see "Risk Factors."

Our Strategy

Our principal purpose is to advance the clinical development program of the Products, which include SkinJectTM a novel, minimally invasive treatment for basal cell carcinoma and potentially other common forms of non-melanoma skin cancer and Teverelix, a next generation gonadotrophin-releasing hormone ("GnRH") antagonist that is a potentially first in market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention ("AUR") episodes due to enlarged prostate. We also seek to opportunistically identify, evaluate and acquire accretive assets, properties or businesses.

SkinJectTM is considered an Investigational New Drug ("IND") by the FDA. In January 2024, we submitted to the FDA a Phase 2 IND clinical protocol to non-invasively treat basal cell carcinoma of the skin using the Product. The clinical protocol was updated in July 2024.

We may also trial SkinJectTM on other forms of skin cancer beyond basal cell carcinoma. Specifically, it may be trialed against squamous cell carcinoma, cutaneous T-cell lymphoma, as well as pre-cancerous lesions, among other clinical indications, subject to the Company having the capital resources available to do so, without any need to amend or expand the scope of the Company's existing licenses.

In addition, our business strategy includes the opportunistic acquisition of other accretive clinical stage life sciences and biotechnology companies. For example, in August 2025, we acquired 98.6% of the issued and outstanding shares of Antev, a UK-based late clinical-stage drug development company which is developing Teverelix. 

Our Strengths

Our key competitive strengths include:


  • A senior management team, led by Dr. Raza Bokhari, that has deep experience in medicine and pharmaceutical science as well as a proven track record in business development and entrepreneurship.

  • Successful completion of a Phase 1 study of SkinJectTM.

  • Potential to treat a range of other common non-melanoma skin cancers as well as pre-cancerous lesions.
     
  • Potential for Teverelix to be a first in market product for cardiovascular high-risk prostate cancer patients and patients with first AUR episodes due to enlarged prostate.

Corporate Structure

An organizational chart showing our basic corporate structure is set forth below (SkinJect and Medicus Pharma Inc. are 100% owned and Antev is 98.6% owned by Medicus Pharma Ltd.):

Corporate History and Information

Our company (formerly, Interactive Capital Partners Corporation) was incorporated pursuant to the Business Corporations Act (Ontario) on April 30, 2008 under the name Interactive Capital Partners Corporation. Prior to the Business Combination (as defined below), the Company existed as a shell company and had no business operations.

On September 29, 2023, the Company completed a business combination (the "Business Combination") with SkinJect, a company existing under the laws of Pennsylvania. The Business Combination was completed pursuant to a business combination agreement dated May 12, 2023, as amended, among the Company, SkinJect and RBx Capital, LP ("RBx"), an investment entity owned and managed by Dr. Raza Bokhari, and resulted in a reverse takeover of Interactive Capital Partners Corporation (the Company as it existed prior to the Business Combination) by the former shareholders of SkinJect, with SkinJect becoming a wholly owned operating subsidiary of the Company, and the Company being renamed "Medicus Pharma Ltd." The structure of the Business Combination is commonly used by companies seeking to become reporting issuers in Canada, as it allows the combined entity to be listed on the TSX Venture Exchange (the "TSXV") at relatively low cost while completing a concurrent equity financing. SkinJect and RBx structured the Business Combination as a reverse takeover for these reasons.

On October 11, 2023, the Company (as it exists after the Business Combination) commenced trading on the TSXV. On November 15, 2024, we completed our initial public offering in the United States and our common shares and our outstanding public warrants to purchase common shares, issued as a component of the units sold by the Company in its U.S. initial public offering with an exercise price of $4.64 and expiration date of November 15, 2029 (the "Public Warrants"), began trading on Nasdaq under the symbols "MDCX" and "MDCXW", respectively. Effective on February 21, 2025, the Company's common shares were voluntarily delisted from the TSXV. The common shares continue to be listed on Nasdaq.


On August 29, 2025, the Company completed the acquisition of 98.6% of the issued and outstanding shares of Antev, a company incorporated under the laws of England and Wales.

The Company's registered and head office is located at One First Canadian Place, 100 King Street West, Suite 3400, Toronto, Ontario M5X 1A4, Canada.

We lease U.S. office space in Conshohocken, Pennsylvania to operate the businesses of our U.S. subsidiaries, Medicus Pharma Inc. and SkinJect, Inc. We also lease office space in Weybridge, U.K. to operate the business of our subsidiary Antev.

Our website address is www.medicuspharma.com. Information contained on our website is not incorporated by reference into this prospectus, and you should not consider information contained on our website to be part of this prospectus or in deciding whether to purchase our securities.

Recent Developments

On October 22, 2025, the Company announced the enrollment of the first patient in the SKNJCT-004 phase 2 clinical study, to non-invasively treat basal cell carcinoma ("BCC") of the skin.

On October 29, 2025, the Company announced a strategic collaboration with the Gorlin Syndrome Alliance ("GSA") to advance compassionate access to SkinJect™ for patients suffering from Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome. Under the collaboration, the Company and the GSA will jointly pursue the Expanded Access IND Program with the FDA to allow patients with multiple, recurrent, or inoperable BCCs to access SkinJect™ under physician-supervised treatment protocols.

On November 13, 2025, the Company announced that it has received full regulatory and ethical approvals in the United Kingdom to expand its ongoing Phase 2 clinical study (SKNJCT-003) evaluating D-MNA to non-invasively treat BCC.

On November 17, 2025, the Company announced that it has submitted an FDA commissioner's national priority voucher application on behalf of (SKNJCT-003) D-MNA to non-invasively treat BCC of the skin.

Effective on November 28, 2025, James Quinlan, Chief Financial Officer of the Company, resigned as an officer and an employee of the Company. Mr. Quinlan had been on a medical leave of absence since September 12, 2025. Effective on December 1, 2025, Carolyn Bonner, President of the Company as well as Acting Chief Financial Officer of the Company since September 12, 2025 in Mr. Quinlan's absence, was appointed as Chief Financial Officer of the Company. Ms. Bonner will also continue to serve as President of the Company, a role she has held since September 2023.

On December 5, 2025, we entered into a warrant inducement agreement with an institutional investor (the "Warrant Inducement Agreement"), pursuant to which the investor agreed to exercise existing warrants to purchase up to 2,680,000 of the Company's common shares issued on July 14, 2025 with an amended exercise price of $1.92 per Common Share, in consideration for receiving 4,020,000 warrants to purchase common shares with an exercise price of $2.00. In accordance with the Warrant Inducement Agreement, the investor exercised its existing warrants for cash, for gross proceeds of approximately $5.1 million to the Company.

On December 15, 2025, the Company announced that its Phase 2 clinical study (SKNJCT-003) evaluating safety and efficacy of D-MNA to non-invasively treat nodular BCC of the skin, has successfully completed enrolment of ninety (90) patients in the United States.


On December 22, 2025, the Company announced that it has entered into a non-binding letter of intent with Reliant AI Inc., a decision-intelligence company for the life sciences, specializing in generative AI, to collaborate on the development of an artificial-intelligence-powered data analytics platform designed to support clinical trial execution through data-driven insights.

Implications of Being an Emerging Growth Company

As a company with less than $1.235 billion in revenues during our last fiscal year, we qualify as an "emerging growth company" as that term is defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). As an emerging growth company we expect to take advantage of specified reduced reporting requirements that are otherwise applicable generally to public companies. These reduced reporting requirements include, but are not limited to:

  • not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended ("Sarbanes-Oxley Act");

  • reduced disclosure about our executive compensation arrangements in our periodic reports, proxy statements and registration statements; and

  • an exemption from the requirements to obtain a non-binding advisory vote on executive compensation or shareholder approval of any golden parachute arrangements.

We may take advantage of these provisions until the last day of our fiscal year following the fifth anniversary of the completion of this offering. However, if certain events occur prior to the end of such five-year period, including if we become a "large accelerated filer," our annual gross revenues exceed $1.235 billion or we issue more than $1 billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period.

The JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. As an emerging growth company, we intend to take advantage of an extended transition period for complying with new or revised accounting standards as permitted by the JOBS Act. We have elected to take advantage of certain of the reduced disclosure obligations in this prospectus and in the registration statement of which this prospectus is a part and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information in this prospectus and that we provide to our shareholders in the future may be different than what you might receive from other public reporting companies in which you hold equity interests.

Implications of Being a Smaller Reporting Company

Additionally, we are a "smaller reporting company," meaning that the market value of our common shares held by non-affiliates plus the proposed aggregate amount of gross proceeds to us as a result of this transaction is less than $700 million and our annual revenue is less than $100 million during the most recently completed fiscal year. As such, we are eligible for exemptions from various reporting requirements applicable to other public companies that are not smaller reporting companies, including, but not limited to, reduced disclosure obligations regarding executive compensation. We may continue to be a smaller reporting company as long as either (i) the market value of our common shares held by non-affiliates is less than $250 million or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our common shares held by non-affiliates is less than $700 million.


RISK FACTORS

Investing in any securities offered pursuant to this prospectus involves a high degree of risk. Please see the risk factors set forth in Part I, Item 1A of our Annual Report, Part II, Item 1A of our Quarterly Report on Form 10-Q for the period ending September 30, 2025, and in other filings we make with the SEC, which are incorporated by reference in this prospectus. Additional risk factors may be included in a prospectus supplement relating to a particular offering of securities. Before making an investment decision, you should carefully consider these risks as well as other information we include or incorporate by reference in this prospectus. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our business operations. These risks could materially affect our business, results of operations or financial condition and cause the value of our securities to decline.


USE OF PROCEEDS

Unless we state otherwise in an accompanying prospectus supplement, we intend to use the net proceeds from the sale of the securities offered by us in primary offerings under this prospectus and any related prospectus supplement for the development of the Products and for general corporate purposes. General corporate purposes may include working capital, acquisitions, retirement of debt and other business opportunities. Pending the application of the net proceeds, we may invest the proceeds in short-term, interest-bearing instruments or other investment-grade securities. We cannot estimate precisely the allocation of the net proceeds from these offerings. Accordingly, our management team will have broad discretion in the application of the net proceeds of these offerings, if any.


DILUTION

We will set forth in a prospectus supplement the following information regarding any material dilution of the equity interests of investors purchasing securities sold by the Company in a primary offering under this prospectus:

  • the net tangible book value per share of our equity securities before and after the offering;

  • the amount of the increase in such net tangible book value per share attributable to the cash payments made by purchasers in the offering; and

  • the amount of the immediate dilution from the public offering price which will be absorbed by such purchasers.

DESCRIPTION OF THE SECURITIES THAT MAY BE OFFERED

The Company may offer common shares, preferred shares, subscription rights, units or warrants with a total value of up to $100,000,000 from time to time under this prospectus, together with any applicable prospectus supplement, at prices and on terms to be determined by market conditions at the time of offering. This prospectus provides you with a general description of the securities the Company may offer. Each time the Company offers securities, it will provide a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities, including, to the extent applicable:

  • designation or classification;

  • aggregate offering price;

  • original issue discount, if any;

  • rates and times of payment of dividends, if any;

  • redemption, conversion or exchange terms, if any;

  • conversion or exchange prices, if any, and, if applicable, any provisions for changes to or adjustments in the conversion or exchange prices in the securities or other property receivable upon conversion or exchange;

  • restrictive covenants, if any;

  • voting or other rights, if any; and

  • important U.S. federal income tax considerations.

A prospectus supplement may also add, update or change information contained in this prospectus or in documents the Company has incorporated by reference. However, no prospectus supplement will offer a security that is not described in this prospectus.

Description of Common Shares

The Company may offer common shares, which the Company may issue independently or together with preferred shares, warrants and/or subscription rights, and the common shares may be separate from or attached to such securities as a unit. See "Description of Share Capital" contained in Exhibit 4.1 to our Annual Report, filed with the SEC on March 28, 2025.

Description of Preferred Shares

Preferred shares may be offered separately or together with other securities, as the case may be. See "Description of Share Capital" contained in Exhibit 4.1 to our Annual Report, filed with the SEC on March 28, 2025.

Description of Subscription Rights

We may issue subscription rights to purchase our common shares, preferred shares or other securities. These subscription rights may be issued independently or together with any other security offered hereby and may or may not be transferable by the shareholder receiving the subscription rights in such offering. In connection with any offering of subscription rights, we may enter into a standby arrangement with one or more underwriters or other purchasers pursuant to which the underwriters or other purchasers may be required to purchase any securities remaining unsubscribed for after such offering.


The applicable prospectus supplement will describe the specific terms of any offering of subscription rights for which this prospectus is being delivered, including the following:

  • the price, if any, for the subscription rights;

  • the exercise price payable for each common share or preferred share upon the exercise of the subscription rights;

  • the number of subscription rights issued to each shareholder;

  • the number and terms of the common shares or preferred shares which may be purchased per each subscription right;

  • the extent to which the subscription rights are transferable;

  • any other terms of the subscription rights, including the terms, procedures and limitations relating to the exchange and exercise of the subscription rights;

  • the date on which the right to exercise the subscription rights shall commence, and the date on which the subscription rights shall expire;

  • the extent to which the subscription rights may include an over-subscription privilege with respect to unsubscribed securities; and

  • if applicable, the material terms of any standby underwriting or purchase arrangement entered into by us in connection with the offering of subscription rights.

The description in the applicable prospectus supplement of any subscription rights we offer will not necessarily be complete and will be qualified in its entirety by reference to the applicable subscription rights certificate, which will be filed with the SEC if we offer subscription rights.

Description of Units

The Company may issue units comprised of one or more of the other securities described in this prospectus in any combination. A unit is typically issued so the holder thereof is also the holder of each security included in the unit. As a result, the holder of a unit will have the rights and obligations of a holder of each security comprising the unit. The agreement, if any, under which a unit is issued may provide that the securities comprising the unit may not be held or transferred separately at any time or at any time before a specified date.

The particular terms and provisions of each issue of units will be described in the related prospectus supplement. This description will include, where applicable:

  • the designation and aggregate number of units offered;

  • the price at which the units will be offered;

  • the currency in which the units are denominated;

  • the terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately;

  • any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units; and

  • any other material terms, conditions and rights of the units.

The Company reserves the right to set forth in a prospectus supplement specific terms of the units that are not within the options and parameters set forth in this prospectus. In addition, to the extent that any particular terms of the units described in a prospectus supplement differ from any of the terms described in this prospectus, the description of such terms set forth in this prospectus shall be deemed to have been superseded by the description of such differing terms set forth in such prospectus supplement with respect to such units.

Description of Warrants

Warrants may be offered separately or together with other securities, as the case may be. The applicable prospectus supplement will include details of the terms and conditions of the warrants being offered, including a description of the instrument under which the warrants will be offered.

The particular terms of each issue of warrants will be described in the related prospectus supplement. This description will include, where applicable:

  • the number of warrants offered;

  • the price at which the warrants will be offered;

  • the currency or currencies in which the warrants will be offered;

  • whether the warrants will be listed on any stock exchange;

  • the designation and terms of the common shares and/or other securities purchasable upon exercise of the warrants;

  • the date on which the right to exercise the warrants will commence and the date on which the right will expire;

  • the number of common shares and/or other securities that may be purchased upon exercise of each warrant and the price at which, and currency or currencies in which, the common shares and/or other securities may be purchased upon exercise of each warrant;

  • the designation and terms of any other securities with which the warrants will be offered, if any, and the number of the warrants that will be offered with each security;

  • if the warrants are issued as a unit with another security, the date or dates, if any, on or after which the warrants and the related securities will be transferable separately;

  • whether the warrants will be subject to redemption or call and, if so, the terms of such redemption or call provisions;

  • material U.S. federal income tax consequences of owning the warrants; and

  • any other material terms or conditions of the warrants.

Prior to the exercise of their warrants, holders of warrants will not have any of the rights of holders of common shares issuable upon exercise of the warrants.


The Company reserves the right to set forth in a prospectus supplement specific terms of the warrants that are not within the options and parameters set forth in this prospectus. In addition, to the extent that any particular terms of the warrants described in a prospectus supplement differ from any of the terms described in this prospectus, the description of such terms set forth in this prospectus shall be deemed to have been superseded by the description of such differing terms set forth in such prospectus supplement with respect to such warrants.


PLAN OF DISTRIBUTION

We may offer and sell the securities in any one or more of the following ways:

  • to or through underwriters, brokers or dealers;

  • directly to one or more other purchasers;

  • through a block trade in which the broker or dealer engaged to handle the block trade will attempt to sell the securities as agent, but may position and resell a portion of the block as principal to facilitate the transaction;

  • through agents on a best-efforts basis;

  • in "at the market" offerings, as defined in Rule 415 under the Securities Act, at negotiated prices, at prices prevailing at the time of sale or at prices related to such prevailing market prices, including sales made directly on the Nasdaq or sales made through a market maker other than on an exchange or other similar offerings through sales agents; or

  • otherwise through any other method permitted by applicable law or a combination of any of the above methods of sale.

In addition, we may enter into option, share lending or other types of transactions that require us to deliver common shares to an underwriter, broker or dealer, who will then resell or transfer the common shares under this prospectus. We may also enter into hedging transactions with respect to our securities. For example, we may:

  • enter into transactions involving short sales of the common shares by underwriters, brokers or dealers;

  • sell common shares short and deliver the shares to close out short positions;

  • enter into option or other types of transactions that require the delivery of common shares to an underwriter, broker or dealer, who will then resell or transfer the common shares under this prospectus; or

  • loan or pledge the common shares to an underwriter, broker or dealer, who may sell the loaned shares or, in the event of default, sell the pledged shares.

We may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement indicates, in connection with those derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party may use securities pledged by or borrowed from us or others to settle those sales or to close out any related open borrowings of common shares, and may use securities received from us in settlement of those derivatives to close out any related open borrowings of common shares. The third party in such sale transactions will be an underwriter and, if not identified in this prospectus, will be identified in the applicable prospectus supplement (or a post-effective amendment). In addition, we may otherwise loan or pledge securities to a financial institution or other third party that in turn may sell the securities short using this prospectus. Such financial institution or other third party may transfer its economic short position to investors in our securities or in connection with a concurrent offering of other securities.

Each time we sell securities, we will provide a prospectus supplement that will name any underwriter, dealer or agent involved in the offer and sale of the securities. Any prospectus supplement will also set forth the terms of the offering, including:

  • the purchase price of the securities and the proceeds we will receive from the sale of the securities;

  • any underwriting discounts and other items constituting underwriters' compensation;

  • any public offering or purchase price and any discounts or commissions allowed or re-allowed or paid to dealers;

  • any commissions allowed or paid to agents;

  • any other offering expenses;

  • any securities exchanges on which the securities may be listed;

  • the method of distribution of the securities;

  • the terms of any agreement, arrangement or understanding entered into with the underwriters, brokers or dealers; and

  • any other information we think is important.

If underwriters or dealers are used in the sale, the securities will be acquired by the underwriters or dealers for their own account. The securities may be sold from time to time by us in one or more transactions:

  • at a fixed price or prices, which may be changed;

  • at market prices prevailing at the time of sale;

  • at prices related to such prevailing market prices;

  • at varying prices determined at the time of sale; or

  • at negotiated prices.

Such sales may be effected:

  • in transactions on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale;

  • in transactions in the over-the-counter market;

  • in block transactions in which the broker or dealer so engaged will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction, or in crosses, in which the same broker acts as an agent on both sides of the trade;

  • through the writing of options; or

  • through other types of transactions.

The securities may be offered to the public either through underwriting syndicates represented by one or more managing underwriters or directly by one or more of such firms. Unless otherwise set forth in the prospectus supplement, the obligations of underwriters or dealers to purchase the securities offered will be subject to certain conditions precedent and the underwriters or dealers will be obligated to purchase all the offered securities if any are purchased. Any public offering price and any discount or concession allowed or reallowed or paid by underwriters or dealers to other dealers may be changed from time to time.


The securities may be sold directly by us or through agents designated by us from time to time. Any agent involved in the offer or sale of the securities in respect of which this prospectus is delivered will be named, and any commissions payable to such agent will be set forth in, the prospectus supplement. Unless otherwise indicated in the prospectus supplement, any such agent will be acting on a best efforts basis for the period of its appointment.

Unless otherwise specified in the related prospectus supplement, all securities we offer, other than common shares, will be new issues of securities with no established trading market. Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. Any common shares sold pursuant to a prospectus supplement will be listed for trading on the Nasdaq or other principal market for our common shares. We may apply to list any series of preferred shares or warrants on an exchange, but we are not obligated to do so. Therefore, there may not be liquidity or a trading market for any series of securities.

Offers to purchase the securities offered by this prospectus may be solicited, and sales of the securities may be made by us directly to institutional investors or others, who may be deemed to be underwriters within the meaning of the Securities Act with respect to any resale of the securities. The terms of any offer made in this manner will be included in the prospectus supplement relating to the offer.

Some of the underwriters, dealers or agents used by us in any offering of securities under this prospectus may be customers of, engage in transactions with, and perform services for us or affiliates of ours in the ordinary course of business. Underwriters, dealers, agents and other persons may be entitled to indemnification against and contribution toward certain civil liabilities, including liabilities under the Securities Act, and to be reimbursed for certain expenses.

Any securities initially sold outside the United States may be resold in the United States through underwriters, dealers or otherwise.

Any underwriters to which offered securities are sold by us for public offering and sale may engage in transactions that stabilize, maintain or otherwise affect the price of the common shares during and after the offering, but those underwriters will not be obligated to do so and may discontinue any market making at any time. Specifically, the underwriters may over-allot or otherwise create a short position in the common shares for their own accounts by selling more common shares than have been sold to them by us. The underwriters may elect to cover any such short position by purchasing common shares in the open market or by exercising the over-allotment option granted to the underwriters. In addition, the underwriters may stabilize or maintain the price of the common shares by bidding for or purchasing common shares in the open market and may impose penalty bids. If penalty bids are imposed, selling concessions allowed to syndicate members or other broker-dealers participating in the offering are reclaimed if common shares previously distributed in the offering are repurchased, whether in connection with stabilization transactions or otherwise. The effect of these transactions may be to stabilize or maintain the market price of the common shares at a level above that which might otherwise prevail in the open market. The imposition of a penalty bid may also affect the price of the common shares to the extent that it discourages resales of the common shares. The magnitude or effect of any stabilization or other transactions is uncertain. These transactions may be effected on the Nasdaq or otherwise and, if commenced, may be discontinued at any time.

In connection with the offering, the underwriters and selling group members may also engage in passive market making transactions in our common shares. Passive market making consists of displaying bids on the Nasdaq limited by the prices of independent market makers and effecting purchases limited by those prices in response to order flow. Rule 103 of Regulation M promulgated by the SEC limits the amount of net purchases that each passive market maker may make and the displayed size of each bid. Passive market making may stabilize the market price of the common shares at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time.

We are subject to the applicable provisions of the Exchange Act and the rules and regulations under the Exchange Act, including Regulation M. This regulation may limit the timing of purchases and sales of any of the common shares offered in this prospectus by any person. The anti-manipulation rules under the Exchange Act may apply to sales of shares in the market and to our activities.


The anticipated date of delivery of the securities offered by this prospectus will be described in the applicable prospectus supplement relating to the offering.

Any broker-dealer participating in the distribution of the common shares may be deemed to be an "underwriter" within the meaning of the Securities Act with respect to any securities such entity sells pursuant to this prospectus.

To comply with the securities laws of some states, if applicable, the securities may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some states the securities may not be sold unless they have been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied with.


LEGAL MATTERS

The validity of the issuance of certain of the securities offered hereby and certain other legal matters as to Canadian law will be passed upon for us by Bennett Jones LLP, Toronto, Canada  and by Paul, Weiss, Rifkind, Wharton & Garrison LLP, New York, New York with respect to the validity of issuance of certain securities and certain legal matters governed by U.S. law. Additional legal matters may be passed on for us, or any underwriters, dealers or agents, by counsel we will name in the applicable prospectus supplement.

EXPERTS

No expert or counsel named in this prospectus as having prepared or certified any part of this prospectus or having given an opinion upon the validity of the securities being registered or upon other legal matters in connection with the registration or offering of the securities was employed on a contingency basis or had, or is to receive, in connection with the offering, a substantial interest, directly or indirectly, in the Company or its subsidiaries. Nor was any such person connected with the Company or any of its subsidiaries as a promoter, managing or principal underwriters, voting trustee, director, officer or employee.

The consolidated balance sheets of the Company and its subsidiaries as of December 31, 2024, and the related consolidated statements of operations and comprehensive loss, shareholders' equity, and cash flows for the year then ended, have been audited by EisnerAmper LLP, independent registered public accounting firm, as stated in their report which is incorporated by reference herein which report includes an explanatory paragraph about the existence of substantial doubt concerning the Company's ability to continue as a going concern. Such financial statements have been incorporated by reference herein in reliance on the report of such firm given upon their authority as experts in accounting and auditing.

The consolidated balance sheets of the Company and subsidiaries as of December 31, 2023, and the related consolidated statements of operations and comprehensive loss, shareholders' equity, and cash flows for the year then ended, have been audited by MNP LLP, independent registered public accounting firm, as stated in their report which is incorporated by reference herein.

WHERE YOU CAN FIND MORE INFORMATION

We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available on the SEC's website at http://www.sec.gov. We also make available free of charge on our website at http://www.medicuspharma.com all materials that we file electronically with the SEC.

As permitted by SEC rules, this prospectus does not contain all of the information we have included in the registration statement and the accompanying exhibits and schedules we file with the SEC. You may refer to the registration statement, exhibits and schedules for more information about us and the securities. The registration statement, exhibits and schedules are available through the SEC's website.

INFORMATION INCORPORATED BY REFERENCE

In this prospectus, we "incorporate by reference" certain information that is filed with the SEC, which means that we can disclose important information to you by referring you to that information. The information we incorporate by reference is an important part of this prospectus, and later information that we file with the SEC will automatically update and supersede this information. The following documents have been filed by us with the SEC and are incorporated by reference into this prospectus:

  • our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as filed with the SEC on March 28, 2025, and the related Amendment to our Annual Report on Form 10-K, as filed with the SEC on April 30, 2025;

  • our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, as filed with the SEC on May 12, 2025;

  • our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025, as filed with the SEC on August 11, 2025;

  • our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, as filed with the SEC on November 14, 2025;

  • our Current Reports on Form 8-K, as filed with the SEC on February 11, 2025, March 11, 2025, March 20, 2025, March 25, 2025, April 28, 2025, May 5, 2025, June 2, 2025, June 5, 2025, June 20, 2025, June 23, 2025, June 30, 2025, July 3, 2025, July 14, 2025, July 23, 2025, July 30, 2025, August 4, 2025, August 22, 2025, September 2, 2025, September 12, 2025, September 18, 2025, October 17, 2025, November 14, 2025, December 1, 2025 and December 8, 2025; and
     
  • the description of our securities contained in Exhibit 4.1 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 28, 2025, and any amendment or report filed for the purpose of updating such description.

Additionally, all documents and reports that we file with the SEC (other than any portion of such filings that are furnished under applicable SEC rules rather than filed) under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") from the date of this prospectus until the completion of the offering under this prospectus shall be deemed to be incorporated in this prospectus by reference. The information contained on or accessible through our website (http://www.medicuspharma.com) is not incorporated into this prospectus.

You may request a copy of these filings, other than an exhibit to these filings unless we have specifically included or incorporated that exhibit by reference into the filing, from the SEC as described under "Where You Can Find More Information" or, at no cost, by writing or telephoning the Company at the following address:

Medicus Pharma Ltd.
Attention: Corporate Secretary
300 Conshohocken State Rd., Suite 200

W. Conshohocken, PA 19428

madesso@medicuspharma.com

You should rely only on the information contained or incorporated by reference in this prospectus, the prospectus supplement, any free writing prospectus that we authorize and any pricing supplement. We have not authorized any person, including any salesman or broker, to provide information other than that provided in this prospectus, any applicable prospectus supplement, any free writing prospectus that we authorize or any pricing supplement. We have not authorized anyone to provide you with different information. We do not take responsibility for, and can provide no assurance as to the reliability of, any information that others may give you. We are not making an offer of the securities in any jurisdiction where the offer is not permitted. You should not assume that the information in this prospectus, any applicable prospectus supplement, any free writing prospectus that we authorize, any pricing supplement or any documents incorporated by reference is accurate as of any date other than the date of the applicable document.

Any statement contained in a document incorporated or deemed to be incorporated by reference into this prospectus will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus, any applicable prospectus supplement or any other subsequently filed document that is deemed to be incorporated by reference into this prospectus modifies or supersedes the statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus.


MEDICUS PHARMA LTD.

PROSPECTUS SUPPLEMENT

November 13, 2026


Keep reading